← Lex Fridman

John Abramson: Big Pharma

Episode 2632022-02-11English

Guests: John Abramson

Listen to this episode00:00 / 2:24:13
Reading settings
Reading preferences
Text size
Download in-depth read
Read offline

In-depth read pending

Downloads are not available yet.

§01Transcript · 00:00–09:48

00:00The jury found Pfizer guilty of fraud

00:02and racketeering violations.

00:04How does Big Pharma affect your mind?

00:06Everyone's allowed their own opinion.

00:08I don't think everyone's allowed their own scientific facts.

00:11Does Pfizer play by the rules?

00:13Pfizer isn't battling the FDA.

00:16Pfizer has joined the FDA.

00:21The following is a conversation with John Abramson,

00:24faculty at Harvard Medical School,

00:26a family physician for over two decades,

00:29and author of the new book, Sickening,

00:32about how Big Pharma broke American healthcare

00:35and how we can fix it.

00:37This conversation with John Abramson

00:40is a critical exploration of the pharmaceutical industry.

00:43I wanted to talk to John

00:45in order to provide a countervailing perspective

00:48to the one expressed in my podcast episode

00:50with the CEO of Pfizer, Albert Borla.

00:55And here, please allow me to say a few additional words

00:58about this episode with the Pfizer CEO,

01:01and in general, about why I do these conversations

01:04and how I approach them.

01:06If this is not interesting to you, please skip ahead.

01:10What do I hope to do with this podcast?

01:13I want to understand human nature,

01:15the best and the worst of it.

01:18I want to understand how power, money,

01:19and fame changes people.

01:21I want to understand why atrocities are committed

01:24by crowds that believe they're doing good.

01:27All this, ultimately, because I want to understand

01:30how we can build a better world together,

01:33to find hope for the future,

01:35and to rediscover each time,

01:38through the exploration of ideas,

01:40just how beautiful this life is.

01:43This, our human civilization,

01:45in all of its full complexity,

01:47the forces of good and evil,

01:49of war and peace, of hate and love.

01:53I don't think I can do this with a heart and mind

01:55that is not open, fragile, and willing to empathize

01:59with all human beings,

02:00even those in the darkest corners of our world.

02:04To attack is easy.

02:06To understand is hard.

02:09And I choose the hard path.

02:11I have learned over the past few months

02:13that this path involves me getting more and more attacked

02:17from all sides.

02:19I will get attacked when I host people

02:21like Jay Bhattacharya or Francis Collins,

02:24Jamie Merzl or Vincent Ricanello,

02:28when I stand for my friend, Joe Rogan,

02:31when I host tech leaders like Mark Zuckerberg,

02:34Elon Musk, and others,

02:36when I eventually talk to Vladimir Putin, Barack Obama,

02:40and other figures that have turned the tides of history.

02:44I have and I will get called stupid, naive, weak,

02:50and I will take these words

02:52with respect, humility, and love, and I will get better.

02:57I will listen, think, learn, and improve.

03:00One thing I can promise is there's no amount of money

03:04or fame that can buy my opinion

03:06or make me go against my principles.

03:09There's no amount of pressure that can break my integrity.

03:13There's nothing in this world I need

03:16that I don't already have.

03:18Life itself is the fundamental gift.

03:21Everything else is just the bonus.

03:24That is freedom.

03:26That is happiness.

03:28If I die today, I will die a happy man.

03:33Now, a few comments about my approach

03:35and lessons learned from the Albert Bourla conversation.

03:39The goal was to reveal as much as I could

03:41about the human being before me

03:43and to give him the opportunity to contemplate in long form

03:48the complexities of his role,

03:49including the tension between making money

03:53and helping people, the corruption

03:55that so often permeates human institutions,

03:58the crafting of narratives through advertisements,

04:00and so on.

04:02I only had one hour,

04:04and so this wasn't the time to address these issues deeply

04:07but to show if Albert struggled with them

04:10in the privacy of his own mind,

04:12and if he would let down the veil of political speak

04:16for a time to let me connect with a man

04:19who decades ago chose to become a veterinarian,

04:22who wanted to help lessen the amount of suffering

04:24in the world.

04:26I had no pressure placed on me.

04:28There were no rules.

04:29The questions I was asking were all mine

04:32and not seen by Pfizer folks.

04:34I had no care whether I ever talked to another CEO again.

04:38None of this was part of the calculation

04:41in my limited brain computer.

04:44I didn't want to grill him.

04:45The way politicians grill CEOs in Congress,

04:48I thought that this approach is easy,

04:51self serving, dehumanizing, and it reveals nothing.

04:56I wanted to reveal the genuine intellectual struggle,

04:59vision, and motivation of a human being,

05:01and if that fails, I trusted the listener

05:04to draw their own conclusion and insights from the result,

05:08whether it's the words spoken

05:10or the words left unspoken or simply the silence.

05:14And that's just it.

05:15I fundamentally trust the intelligence of the listener, you.

05:21In fact, if I criticize the person too hard

05:24or celebrate the person too much,

05:26I feel I fail to give the listener

05:29a picture of the human being that is uncontaminated

05:32by my opinion or the opinion of the crowd.

05:36I trust that you have the fortitude and the courage

05:39to use your own mind, to empathize, and to think.

05:43Two practical lessons I took away.

05:46First, I will more strongly push

05:48for longer conversations of three, four, or more hours

05:52versus just one hour.

05:5360 minutes is too short for the guest to relax

05:56and to think slowly and deeply,

05:58and for me to ask many follow up questions

06:00or follow interesting tangents.

06:03Ultimately, I think it's in the interest of everyone,

06:05including the guest, that we talk in true long form

06:09for many hours.

06:11Second, these conversations with leaders

06:13can be aided by further conversations

06:16with people who wrote books about those leaders

06:18or their industries.

06:20Those that can steel man each perspective

06:22and attempt to give an objective analysis.

06:25I think of Teddy Roosevelt's speech

06:26about the man in the arena.

06:28I want to talk to both the men and women in the arena

06:32and the critics and the supporters in the stands.

06:36For the former, I lean toward wanting to understand

06:38one human being's struggle with the ideas.

06:43For the latter, I lean towards understanding

06:45the ideas themselves.

06:48That's why I wanted to have this conversation

06:50with John Abramson, who is an outspoken critic

06:53of the pharmaceutical industry.

06:55I hope it helps add context and depth

06:58to the conversation I had with the Pfizer CEO.

07:02In the end, I may do worse than I could have or should have.

07:06Always, I will listen to the criticisms without ego

07:10and I promise I will work hard to improve.

07:14But let me say finally that cynicism is easy.

07:20Optimism, true optimism is hard.

07:24It is the belief that we can and we will

07:28build a better world and that we can only do it together.

07:32This is the fight worth fighting.

07:35So here we go.

07:36Once more into the breach, dear friends.

07:39I love you all.

07:41This is the Lex Friedman podcast.

07:43To support it, please check out our sponsors

07:46in the description.

07:47And now, here's my conversation with John Abramson.

07:52Your faculty at Harvard Medical School,

07:55your family physician for over two decades,

07:57rated one of the best family physicians in Massachusetts,

08:01you wrote the book, Overdose to America,

08:03and the new book coming out now called Sickening

08:07about how Big Pharma broke American healthcare,

08:10including science and research, and how we can fix it.

08:14First question, what is the biggest problem with Big Pharma

08:18that it fixed would be the most impactful?

08:21So if you can snap your fingers and fix one thing,

08:24what would be the most impactful, you think?

08:26The biggest problem is the way they

08:30determine the content, the accuracy,

08:35and the completeness of what doctors believe

08:39to be the full range of knowledge

08:42that they need to best take care of their patients.

08:46So that with the knowledge having been taken over

08:51by the commercial interests, primarily

08:53the pharmaceutical industry, the purpose of that knowledge

08:57is to maximize the profits that get returned

09:00to investors and shareholders, and not to optimize

09:04the health of the American people.

09:07So rebalancing that equation would be the most important

09:11thing to do to get our healthcare back aimed

09:15in the right direction.

09:16Okay, so there's a tension between helping people

09:20and making money, so if we look at particularly

09:24the task of helping people in medicine, in healthcare,

09:29is it possible if money is the primary sort of mechanism

09:35by which you achieve that as a motivator,

09:38is it possible to get that right?

09:39I think it is, Lex, but I think it is not possible

09:43without guardrails that maintain the integrity

09:46and the balance of the knowledge.

§02Transcript · 09:48–21:09

09:48Without those guardrails, it's like trying to play

09:52a professional basketball game without referees

09:54and having players call their own fouls.

09:57But the players are paid to win, and you can't count

10:01on them to call their own fouls, so we have referees

10:03who are in charge.

10:05We don't have those referees in American healthcare.

10:08That's the biggest way that American healthcare

10:13is distinguished from healthcare in other wealthy nations.

10:17So okay, you mentioned Milton Friedman,

10:19and you mentioned his book called Capitalism and Freedom.

10:24He writes that there are only three legitimate functions

10:27of government to preserve law and order,

10:30to enforce private contracts, and to ensure

10:33that private markets work.

10:36You said that that was a radical idea at the time,

10:40but we're failing on all three.

10:41How are we failing?

10:43And also maybe the bigger picture is what are the strengths

10:47and weaknesses of capitalism when it comes to medicine

10:50and healthcare?

10:51Can we separate those out?

10:53Because those are two huge questions.

10:55So how we're failing on all three,

10:58and these are the minimal functions that our guru

11:03of free market capitalism said the government

11:06should perform, so this is the absolute baseline.

11:11On preserving law and order, the drug companies

11:14routinely violate the law in terms of their marketing,

11:20and in terms of their presentation

11:26of the results of their trials.

11:29I know this because I was an expert in litigation

11:32for about 10 years.

11:35I presented some of what I learned in civil litigation

11:40to the FBI and the Department of Justice,

11:42and that case led to the biggest criminal fine

11:46in US history as of 2009.

11:49And I testified in a federal trial in 2010,

11:56and the jury found Pfizer guilty of fraud

12:00and racketeering violations.

12:02In terms of violating the law, it's a routine occurrence.

12:07The drug companies have paid $38 billion worth of fines

12:10from I think 1991 to 2017.

12:15It's never been enough to stop the misrepresentation

12:21of their data, and rarely are the fines greater

12:25than the profits that were made.

12:29Executives have not gone to jail for misrepresenting data

12:34that have involved even tens of thousands of deaths

12:38in the case of Vioxx, OxyContin as well.

12:42And when companies plead guilty to felonies,

12:45which is not an unusual occurrence,

12:48the government usually allows the companies,

12:51the parent companies, to allow subsidiaries to take the plea

12:56so that they are not one step closer

12:58to getting disbarred from Medicare,

13:01not being able to participate in Medicare.

13:03So in that sense, there is a mechanism

13:11that is appearing to impose law and order

13:15on drug company behavior, but it's clearly not enough.

13:18It's not working.

13:19Can you actually speak to human nature here?

13:24Are people corrupt?

13:26Are people malevolent?

13:28Are people ignorant that work at the low level

13:32and at the high level at Pfizer, for example,

13:36at big pharma companies, how is this possible?

13:40So I believe, just on a small tangent,

13:43that most people are good.

13:45And I actually believe if you join big pharma,

13:48so a company like Pfizer, your life trajectory

13:52often involves dreaming and wanting

13:56and enjoying helping people.

13:58Yes.

13:59And so, and then we look at the outcomes

14:03that you're describing, and it looks,

14:07and that's why the narrative takes hold

14:09that Pfizer CEO, Al Bobrola, who I talked to, is malevolent.

14:15The sense is these companies are evil.

14:19So if the different parts, the people, are good

14:24and they want to do good, how are we getting these outcomes?

14:27Yeah, I think it has to do with the cultural milieu

14:33that this is unfolding in.

14:35And we need to look at sociology to understand this,

14:41that when the cultural milieu is set up

14:49to maximize the returns on investment

14:52for shareholders and other venture capitalists

14:55and hedge funds and so forth,

14:57when that defines the culture

15:00and the higher up you are in the corporation,

15:04the more you're in on the game of getting rewarded

15:10for maximizing the profits of the investors,

15:13that's the culture they live in.

15:15And it becomes normative behavior

15:19to do things with science that look normal

15:25in that environment and are shared values

15:28within that environment by good people

15:31whose self evaluation becomes modified

15:34by the goals that are shared by the people around them.

15:39And within that milieu, you have one set of standards,

15:44and then the rest of good American people

15:48have the expectation that the drug companies

15:50are trying to make money, but that they're playing

15:53by rules that aren't part of the insider milieu.

15:59That's fascinating, the game they're playing

16:02modifies the culture of inside the meetings,

16:07inside the rooms, day to day,

16:10that there's a bubble that forms.

16:12Like we're all in bubbles of different sizes.

16:15And that bubble allows you to drift in terms

16:18of what you see as ethical and unethical.

16:24Because you see the game as just part of the game.

16:28So marketing is just part of the game.

16:32Paying the fines is just part of the game of science.

16:36And without guardrails, it becomes

16:40even more part of the game.

16:42You keep moving in that direction.

16:44If you're not bumping up against guardrails.

16:48And I think that's how we've gotten

16:49to the extreme situation we're in now.

16:53So, like I mentioned, I spoke with Pfizer CEO,

16:57Albert Berla, and I'd like to raise with you

17:00some of the concerns I raised with him.

17:03So one, you already mentioned, I raised the concern

17:07that Pfizer's engaged in aggressive advertising campaigns.

17:11As you can imagine, he said no.

17:15What do you think?

17:18I think you're both right.

17:21I think that the, I agree with you,

17:23that the aggressive advertising campaigns

17:27do not add value to society.

17:30And I agree with him that they're, for the most part, legal.

17:34And it's the way the game is played.

17:37Right, so, sorry to interrupt,

17:38but oftentimes his responses are,

17:44especially now, he's been CEO for only like two years,

17:47three years, he says Pfizer was a different company,

17:50we've made mistakes, right, in the past.

17:53We don't make mistakes anymore.

17:56That there's rules, and we play by the rules.

18:00So like, with every concern raised,

18:02there's very, very strict rules, as he says.

18:06In fact, he says sometimes way too strict.

18:08And we play by them.

18:10And so in that sense, advertisement,

18:12it doesn't seem like it's too aggressive,

18:14because it's playing by the rules.

18:17And relative to the other, again, it's the game.

18:19Relative to the other companies,

18:22it's actually not that aggressive.

18:24Relative to the other big pharma companies.

18:26Yes, yes, I hope we can quickly get back

18:29to whether or not they're playing by the rules,

18:31but in general.

18:32But let's just look at the question

18:34of advertising specifically.

18:36I think that's a good example of what it looks like

18:39from within that culture, and from outside that culture.

18:44He's saying that we follow the law on our advertising.

18:49We state the side effects,

18:51and we state the FDA approved indications,

18:53and we do what the law says we have to do for advertising.

18:57And I have not, I've not been an expert in litigation

19:01for a few years, and I don't know what's going on currently,

19:04but let's take him at his word.

19:07It could be true, it might not be, but it could be.

19:09But if that's true, in his world, in his culture,

19:15that's ethical business behavior.

19:18From a common sense person's point of view,

19:22a drug company paying highly skilled media folks

19:27to take the information about the drug

19:30and create the illusion, the emotional impact,

19:34and the takeaway message for viewers of advertisements

19:38that grossly exaggerate the benefit of the drug

19:41and minimize the harms, it's sociopathic behavior

19:45to have viewers of ads leave the ad

19:49with an unrealistic impression

19:52of the benefits and harms of the drug.

19:56And yet he's playing by the rules,

19:58he's doing his job as CEO

20:01to maximize the effect of his advertising,

20:04and if he doesn't do it, this is a key point,

20:07if he doesn't do it, he'll get fired and the next guy will.

20:11So the people that survive in the company,

20:13the people that get raises in the company,

20:16move up in the company are the ones that play by the rules,

20:19and that's how the game solidifies itself.

20:21But the game is within the bounds of the law.

20:24Sometimes, most of the time, not always.

20:26We'll return to that question.

20:29I'm actually more concerned

20:31about the effect of advertisement

20:34in a kind of much larger scale

20:39on the people that are getting funded

20:43by the advertisement in self censorship,

20:46just like more subtle, more passive pressure

20:50to not say anything negative.

20:52Because I've seen this, and I've been saddened by it,

20:57that people sacrifice integrity in small ways

21:03when they're being funded by a particular company.

21:06They don't see themselves as doing so,

§03Transcript · 21:09–30:48

21:09but you can just clearly see that the space of opinions

21:12that they're willing to engage in,

21:15or a space of ideas they're willing to play with,

21:18is one that doesn't include negative,

21:22anything that could possibly be negative about the company.

21:25They just choose not to.

21:27Because, you know, why?

21:28And that's really sad to me,

21:30that if you give me a hundred bucks,

21:33I'm less likely to say something negative about you.

21:38That makes me sad.

21:39Because the reason I wouldn't say something negative

21:42about you, I prefer, is the pressure of friendship

21:45and human connection, those kinds of things.

21:48So I understand that.

21:50That's also a problem, by the way,

21:52sort of having dinners and shaking hands,

21:54and oh, aren't we friends?

21:56But the fact that money has that effect

21:58is really sad to me.

22:00On the news media, on the journalists, on scientists,

22:05that's scary to me.

22:06But of course, the direct advertisement to consumers,

22:09like you said, is a potentially very negative effect.

22:11I wanted to ask if what you think

22:14is the most negative impact of advertisement,

22:17is it that direct to consumer on television?

22:20Is it advertisement of the doctors?

22:22Which I'm surprised to learn,

22:24I was vaguely looking at,

22:26is more spent on advertising to doctors than to consumers.

22:32That's really confusing to me.

22:34It's fascinating, actually.

22:35And then also, obviously, the law side of things

22:38is the lobbying dollars,

22:40which I think is less than all of those.

22:42But anyway, it's in the ballpark.

22:44What concerns you most?

22:46Well, it's the whole nexus of influence.

22:49There's not one thing, and they don't invest all their,

22:53they don't put all their eggs in one basket.

22:55It's a whole surround sound program here.

23:01But in terms of advertisements,

23:04let's take the advertisement.

23:06Trulicity is a diabetes drug,

23:09for type two diabetes, an injectable drug.

23:12And it lowers blood sugar just about as well

23:15as Metformin does.

23:18Metformin costs about $4 a month.

23:21Trulicity costs, I think, $6,200 a year.

23:25So $48 a year versus $6,200.

23:29Trulicity has distinguished itself

23:31because the manufacturer did a study

23:35that showed that it significantly reduces

23:37the risk of cardiovascular disease in diabetics.

23:41And they got approval on the basis of that study,

23:44that very large study being statistically significant.

23:47So the ads obviously extol the virtues of Trulicity

23:53because it reduces the risk of heart disease and stroke,

23:56and that's one of the major morbidities,

23:59risks of type two diabetes.

24:01What the ad doesn't say is that you have to treat

24:03323 people to prevent one nonfatal event

24:08at a cost of $2.7 million.

24:11And even more importantly than that,

24:13what the ad doesn't say is that the evidence shows

24:17that engaging in an active, healthy lifestyle program

24:22reduces the risk of heart disease and strokes

24:24far more than Trulicity does.

24:28Now, to be fair to the company, the sponsor,

24:32there's never been a study that compared Trulicity

24:37to lifestyle changes.

24:39But that's part of the problem of our advertising.

24:42You would think in a rational society

24:45that was way out on a limb as a lone country

24:50besides New Zealand that allows

24:52direct to consumer advertising,

24:54that part of allowing direct to consumer advertising

24:59would be to mandate that the companies establish

25:03whether their drug is better than,

25:05say, healthy lifestyle adoption

25:07to prevent the problems that they claim to be preventing.

25:11But we don't require that.

25:13So the companies can afford to do very large studies

25:17so that very small differences

25:19become statistically significant.

25:21And their studies are asking the question,

25:23how can we sell more drug?

25:25They're not asking the question,

25:27how can we prevent cardiovascular disease

25:30in people with type 2 diabetes?

25:32And that's how we get off in this,

25:34we're now in the extreme arm of this distortion

25:38of our medical knowledge of studying

25:41how to sell more drugs than how to make people more healthy.

25:45That's a really great thing to compare to,

25:48is lifestyle changes.

25:51Because that should be the bar.

25:53If you do some basic diet, exercise,

25:56all those kinds of things,

25:58how does this drug compare to that?

26:00Right, right.

26:01And that study was done, actually, in the 90s.

26:04It's called the Diabetes Prevention Program.

26:06It was federally funded by the NIH

26:09so that there wasn't this drug company imperative

26:13to just try to prove your drug was better than nothing.

26:16And it was a very well designed study,

26:19randomized controlled trial

26:22in people who were at high risk of diabetes,

26:25so called pre diabetics.

26:26And they were randomized to three different groups,

26:30a placebo group, a group that got treated with metformin,

26:34and a group that got treated

26:36with intensive lifestyle counseling.

26:38So this study really tested

26:42whether you can get people in a randomized controlled trial

26:46assigned to intensive lifestyle changes,

26:49whether that works.

26:50Now the common wisdom amongst physicians,

26:54and I think in general,

26:56is that you can't get people to change.

26:57You know, you can do whatever you want,

26:59you can stand on your head,

27:00you can beg and plead, people won't change.

27:02So give it up and let's just move on with the drugs

27:05and not waste any time.

27:06Except this study that was published

27:08in the New England Journal, I think in 2002,

27:11shows that's wrong.

27:12That the people who were in the intensive lifestyle group

27:16ended up losing 10 pounds,

27:18exercising five times a week, maintaining it,

27:21and reduced their risk of getting diabetes by 58%,

27:26compared to the metformin group,

27:27which reduced its risk of getting diabetes by 31%.

27:32So that exact study was done

27:34and it showed that lifestyle intervention is the winner.

27:38Who, as a small tangent, is the leader,

27:44who is supposed to fight for the side of lifestyle changes?

27:49Where's the big pharma version of lifestyle changes?

27:54Who's supposed to have the big bully pulpit,

27:57the big money behind lifestyle changes?

28:00In your sense, because that seems to be missing

28:03in a lot of our discussions about health policy.

28:06Right, that's exactly right.

28:08And the answer is that we assume

28:12that the market has to solve all of these problems.

28:15And the market can't solve all of these problems.

28:18There needs to be some way of protecting the public interest

28:23for things that aren't financially driven.

28:26So that the overriding question has to be

28:28how best to improve Americans health,

28:31not companies funding studies to try and prove

28:36that their new inexpensive drug is better

28:39and should be used.

28:40Well, some of that is also people sort of like yourself.

28:45I mean, it's funny, you spoke with Joe Rogan.

28:48He constantly espouses lifestyle changes.

28:50So some of it is almost like understanding the problems

28:55that big pharma is creating in society

28:58and then sort of these influential voices

29:02speaking up against it.

29:03So whether they're scientists or just regular communicators.

29:08Yeah, I think you gotta tip your hat to Joe

29:11for getting that message out.

29:13And he clearly believes it and does his best.

29:17But it's not coming out in the legitimate avenues,

29:21in the legitimate channels that are evidence based medicine

29:26and from the sources that the docs are trained to listen to

29:32and modify their patient care on.

29:34Now, it's not 100%.

29:36I mean, there are articles in the big journals

29:40about the benefits of lifestyle,

29:42but they don't carry the same gravitas

29:45as the randomized controlled trials

29:48that test this drug against placebo

29:50or this drug against another drug.

29:52So the Joe Rogans of the world keep going.

29:55I tip my hat.

29:57But it's not gonna carry the day for most of the people

30:00until it has the legitimacy of the medical establishment.

30:04Yeah, like something that the doctors

30:05really pay attention to.

30:07Well, there's an entire mechanism established

30:09for testing drugs.

30:11There's not an entire mechanism established

30:14in terms of scientific rigor of testing lifestyle changes.

30:17I mean, it's more difficult.

30:20I mean, everything's difficult in science.

30:23That science that involves humans, especially.

30:27But it's just, these studies are very expensive.

30:30They're difficult.

30:31It's difficult to find conclusions

30:33and to control all the variables.

30:35And so it's very easy to dismiss them

30:37unless you really do a huge study that's very well funded.

30:40And so maybe the doctors just lean

30:42towards the simpler studies over and over,

30:45which is what the drug companies fund.

§04Transcript · 30:48–40:46

30:48They can control more variables.

30:50See, but the control there is sometimes

30:56by hiding things too, right?

31:00So sometimes you can just say

31:03that this is a well controlled study

31:06by pretending there's a bunch of other stuff.

31:09It's just ignoring the stuff that could be correlated.

31:13It could be the real cause of the effects you're seeing,

31:15all that kind of stuff.

31:17So money can buy ignorance, I suppose, in science.

31:21It buys the kind of blinders that are on

31:24that don't look outside the reductionist model.

31:28And that's another issue is that we kind of,

31:31nobody says to doctors in training,

31:34only listen to reductionist studies and conclusions

31:39and methods of promoting health.

31:42Nobody says that explicitly.

31:43But the respectable science

31:47has to do with controlling the factors.

31:49And I mean, it just doesn't make sense to me.

31:54I'm gonna pick on trulicity

31:55because it's such an obvious example,

31:57but it's not more egregious than many others.

32:01It doesn't make sense to me to allow a drug

32:03to be advertised as preventing cardiovascular disease

32:06when you haven't included lifestyle changes

32:09as an arm in the study.

32:11It's just so crystal clear that the purpose of that study

32:15is to sell trulicity.

32:17It's not to prevent cardiovascular disease.

32:21If we were in charge, I would try to convince you

32:24that anywhere that study, the results of that study

32:27were presented to physicians,

32:31it would be stamped in big red letters,

32:33this study did not compare trulicity to lifestyle changes.

32:37They need to know that.

32:38And the docs are kind of trained,

32:40these blinders get put on,

32:42and they're trained to kind of forget that that's not there.

32:46Do you think, so first of all,

32:48that's a small or big change to advertisement

32:51that seems obvious to say,

32:54like in force that it should be compared

32:56to lifestyle changes.

32:59Do you think advertisements, period,

33:01in the United States for pharmaceutical drugs

33:04should be banned?

33:05I think they can't be banned.

33:07So it doesn't matter what I think.

33:09Okay, let's say you were a dictator,

33:13and two, why can't they be banned?

33:15Okay.

33:16Answer either one.

33:18I believe, I've been told by lawyers who I trust,

33:22that the freedom of speech in the U.S. Constitution

33:27is such that you can't ban them,

33:29that you could ban cigarettes and alcohol,

33:33which have no therapeutic use,

33:35but drugs have a therapeutic use,

33:37and advertisements about them can't be banned.

33:41Let's assume that they can't be,

33:43because we know they won't be anyway,

33:46but let's assume they can't be,

33:49and especially our Supreme Court now

33:51would be unlikely to take that seriously.

33:55But that's not the issue.

33:57The issue is that if the drug companies

34:00want to spend their money advertising,

34:02they should have to have independent analysis

34:06of the message that the viewers are left with

34:10about the drug, so that it's realistic.

34:13What's the chance the drug will help them?

34:15Well, in true city, it's one out of 323.

34:19322 people aren't gonna benefit

34:21from the cardiovascular reduction, risk reduction.

34:25What's the true cost?

34:26When drugs advertise that you may be able to get this

34:30for a $25 copay or something,

34:33tens of thousands of dollars a year drug,

34:35for a $25 copay, what an enormous disservice that is

34:40to misrepresent the cost to society.

34:42That should not be allowed.

34:44So you should have to make it clear to the viewers

34:48how many people are gonna benefit,

34:49what's your chance of benefiting?

34:51How does it compare to lifestyle changes

34:53or less expensive therapies?

34:55What do you give up if you use a less expensive therapy

34:58or gain, perhaps?

34:59And how much it costs.

35:01How much it costs.

35:02Now, that can go either way,

35:03because if you say Humira costs $72,000

35:06and it's no more effective as a first line drug

35:08than methotrexate, which costs $480,

35:12people might say, I want the expensive drug

35:15because I can get it for a $25 copay.

35:17So you'd have to temper that a little bit.

35:21Oh, you mean people are so, they don't care.

35:25They don't care.

35:26Their insurance is gonna cover it and it's a $25 copay,

35:29but we could figure out how to deal with that.

35:31The main point is that if we assume

35:35that advertisements are gonna keep going, and they are,

35:38we could require that there be outside evaluation

35:45of the message that reasonable, unbiased viewers

35:48take away from the ads,

35:50and the ads would have to tell the truth about the drug.

35:55And the truth should have sub truth guardrails,

36:00meaning like the cost that we talked about,

36:03the effects compared to things that actually,

36:07lifestyle changes, just these details,

36:11very strict guardrails of what actually has to be specified.

36:16And I would make it against the law

36:19to have family picnics or dogs catching Frisbees in the ads.

36:23So, you mean 95% of the ads, yes.

36:28I mean, there's something dark and inauthentic

36:32about those advertisements, but they seem,

36:34I mean, I'm sure they're being done

36:36because they work for the target audience.

36:43And then the doctors too.

36:46Can you really buy a doctor's opinion?

36:48Why does it have such an effect on doctors?

36:52Advertisement to doctors, like you as a physician,

36:55again, like from everything I've seen, people love you.

36:58And I've just, people should definitely look you up from,

37:04there's a bunch of videos of you giving talks on YouTube,

37:09and it's just, it's so refreshing to hear

37:14just the clarity of thought about health policy,

37:17about healthcare, just the way you think

37:19throughout the years.

37:20Thank you.

37:21So like, it's easy to think about like,

37:23maybe you're criticizing Big Pharma,

37:25that's one part of the message that you're talking about,

37:28but that's not like, your brilliance actually shines

37:33in the positive, in the solutions and how to do it.

37:35So as a doctor, what affects your mind?

37:40And how does Big Pharma affect your mind?

37:43Number one, the information that comes through

37:46legitimate sources that doctors have been taught

37:50to rely on, evidence based medicine,

37:52the articles in peer reviewed journals,

37:55the guidelines that are issued.

37:57Now, those are problematic,

37:59because when an article is peer reviewed

38:03and published in a respected journal,

38:06people and doctors obviously assume

38:10that the peer reviewers have had access to the data

38:15and they've independently analyzed the data,

38:18and they corroborate the findings in the manuscript

38:21that was submitted, or they give feedback to the authors

38:25and say, we disagree with you on this point,

38:28and would you please check our analysis

38:30and if you agree with us, make it.

38:32That's what they assume the peer review process is,

38:35but it's not.

38:36The peer reviewers don't have the data.

38:39The peer reviewers have the manuscript

38:41that's been submitted by the,

38:44usually in conjunction with or by the drug company

38:49that manufactures the drug.

38:51So peer reviewers are unable to perform the job

38:57that doctors think they're performing

38:59to vet the data to assure that it's accurate

39:03and reasonably complete.

39:05They can't do it.

39:07And then we have the clinical practice guidelines,

39:09which are increasingly more important

39:11as the information, the flow of information

39:15keeps getting brisker and brisker,

39:18and docs need to get to the bottom line quickly.

39:22Clinical practice guidelines become much more important.

39:25And we assume that the authors

39:28of those clinical practice guidelines

39:30have independently analyzed the data

39:32from the clinical trials and make their recommendations

39:35that set the standards of care based on their analysis.

39:39That's not what happens.

39:40The experts who write the clinical trials

39:44rely almost entirely on the publications

39:49presenting the results of the clinical trials,

39:51which are peer reviewed,

39:52but the peer reviewers haven't had access to the data.

39:56So we've got a system of the highest level of evidence

40:01that doctors have been trained over and over again

40:03to rely on to practice evidence based medicine

40:06to be good doctors that has not been verified.

40:10Do you think that data that's coming

40:14from the pharma companies,

40:17do you think there,

40:19what level of manipulation is going on with that data?

40:22Is it at the study design level?

40:25Is it at literally there's some data

40:28that you just keep off, keep out of the charts,

40:33keep out of the aggregate analysis that you then publish?

40:38Or is it the worst case,

40:41which is just change some of the numbers?

40:44It happened.

40:45All three happened.

§05Transcript · 40:46–50:51

40:46I can't, I don't know what the denominator is,

40:48but I spent about 10 years in litigation.

40:51And for example, in Vioxx,

40:54which was withdrawn from the market in 2004

40:57in the biggest drug recall in American history,

41:02the problem was that it got recalled

41:06when a study that Merck sponsored

41:08showed that Vioxx doubled the risk,

41:10more than doubled the risk of heart attacks,

41:12strokes, and blood clots, serious blood clots.

41:16It got pulled then.

41:18But there was a study, a bigger study

41:20that had been published in 2000

41:22in the New England Journal of Medicine

41:24that showed that Vioxx was a better drug

41:28for arthritis and pain,

41:32not because it was more effective.

41:34It's no more effective than Aleve or Advil,

41:37but because it was less likely

41:40to cause serious GI complications,

41:43bleeds and perforations in the gut.

41:46Now, in that study that was published

41:48in the New England Journal that was never corrected,

41:51it was a little bit modified 15 months

41:55after the drug was taken off the market,

41:57but never corrected, Merck left out three heart attacks.

42:01And the FDA knew that Merck left out three heart attacks,

42:05and the FDA's analysis of the data from that study

42:10said that the FDA wasn't gonna do the analysis

42:14without the three heart attacks in it.

42:16And the important part of this story

42:19is that there were 12 authors listed on that study

42:23in the New England Journal.

42:24Two were Merck employees.

42:26They knew about the three heart attacks

42:27that had been omitted.

42:29The other 10 authors, the academic authors,

42:34didn't know about it.

42:35They hadn't seen that data.

42:38So Merck just, they had an excuse.

42:41It's complicated, and the FDA didn't accept it,

42:44so there's no reason to go into it.

42:46But Merck just left out the three heart attacks.

42:48And the three heart attacks,

42:50it may seem three heart attacks in a 10,000 person study

42:52may seem like nothing,

42:54except they completely changed the statistics

42:57so that had the three heart attacks been included,

43:00the only conclusion that Merck could have made

43:02was that Vioxx significantly increased

43:04the risk of heart attack.

43:06And they abbreviated their endpoint

43:09from heart attack, strokes, and blood clots

43:12to just heart attacks.

43:13Yeah.

43:14So those are, maybe in their mind,

43:17they're also playing by the rules

43:18because of some technical excuse that you mentioned

43:20that was rejected.

43:22How can this, because this is crossing the line.

43:24No, no, let me interrupt.

43:25No, that's not true.

43:28The study was completed.

43:30The blind was broken, meaning they looked at the data.

43:34In March of 2000, the article was published

43:37in the New England Journal in November of 2000.

43:40In March of 2000, there was an email by the head scientist

43:45that was published in the Wall Street Journal

43:49that said the day that the data were unblinded,

43:53that it's a shame that the cardiovascular events are there,

43:58but the drug will do well and we will do well.

44:08But removing the three heart attacks,

44:10how does that happen?

44:12Like who has to convince themselves?

44:16Is this pure malevolence?

44:19You have to be the judge of that,

44:21but the person who was in charge of the Data Safety

44:24Monitoring Board issued a letter that said

44:28they'll stop counting cardiovascular events

44:32a month before the trial is over

44:35and they'll continue counting GI events.

44:38And that person got a contract to consult with Merck

44:43for $5,000 a day, I think for 12 days a year,

44:47for one or two years that was signed, that contract

44:53was signed within two weeks of the decision

44:58to stop counting heart attacks.

45:00I wanna understand that man or woman.

45:04I wanna, I want, it's the, I've been reading a lot

45:08about Nazi Germany and thinking a lot

45:10about the good Germans because I want to understand

45:15so that we can each encourage each other

45:20to take the small heroic actions that prevents that.

45:23Because it feels to me, removing malevolence

45:27from the table where it's just a pure psychopathic person,

45:31that there's just a momentum created

45:34by the game like you mentioned.

45:35And so it takes reversing the momentum within the company,

45:40I think requires many small acts of heroism.

45:46Not gigantic, I'm going to leave and become a whistleblower

45:50and publish a book about it.

45:52But small, quiet acts of pressuring against this.

45:57Like, what are we doing here?

45:59We're trying to help people.

46:00Is this the right thing to do?

46:01Looking in the mirror constantly asking,

46:03is this the right thing to do?

46:05I mean, that's how, that's what integrity is.

46:07Acknowledging the pressures you're under

46:11and then still be able to zoom out

46:13and think what is the right thing to do here.

46:16But the data, hiding the data makes it too easy

46:21to live in ignorance.

46:22So like within those, inside those companies.

46:29So your idea is that the reviewers should see the data.

46:34That's one step.

46:36So to even push back on that idea is,

46:40I assume you mean the data remains private

46:43except to the peer reviews, reviewers.

46:47The problem with, of course, as you probably know

46:49is the peer review process is not perfect.

46:53You know, it's individuals.

46:55It feels like there should be a lot more eyes on the data

46:58than just the peer reviewers.

47:00Yes, this is not a hard problem to solve.

47:03When a study is completed,

47:06a clinical study report is made.

47:10And it's usually several thousand pages.

47:12And what it does is it takes the raw patient data

47:15and it tabulates it in the ways it's supposedly and usually

47:22in the ways that the company has pre specified.

47:25So that you then end up with a searchable,

47:28let's say 3000 page document.

47:30As I became more experienced as an expert in litigation,

47:36I could go through those documents pretty quickly.

47:39Quickly may mean 20 hours or 40 hours,

47:42but it doesn't mean three months of my work.

47:45And see if the companies,

47:49if the way the company has analyzed the data

47:51is consistent with the way,

47:53with their statistical analysis plan

47:55and their pre specified outcome measures.

48:00It's not hard.

48:01And I think you're right.

48:02Peer reviewers, I don't peer review clinical trials,

48:06but I peer review other kinds of articles.

48:09I have to do one on the airplane on the way home.

48:11And it's hard.

48:12I mean, we're just ordinary mortal people volunteering to.

48:15Unpaid, the motivation is not clear.

48:19The motivation is to keep,

48:23to be a good citizen in the medical community

48:27and to be on friendly terms with the journals

48:31so that if you wanna get published,

48:33there's sort of an unspoken incentive.

48:37As somebody who enjoys game theory,

48:39I feel like that motivation is good,

48:42but it could be a lot better.

48:44Yes, you should get more recognition

48:46or in some way academic credit for it.

48:50It should go to your career advancement.

48:53If it's an important paper

48:54and you recognize it's an important paper

48:56as a great peer reviewer,

48:58that this is not in that area

49:01where it's like clearly a piece of crap paper

49:05or clearly an awesome paper

49:08that doesn't have controversial aspects to it

49:10and it's just a beautiful piece of work.

49:13Okay, those are easy.

49:14And then there is like the very difficult gray area,

49:17which may require many, many days of work

49:20on your part as a peer reviewer.

49:21So it's not just a couple hours,

49:24but really seriously reading.

49:27Like some papers can take months to really understand.

49:30So if you really wanna struggle,

49:33there has to be an incentive for that struggle.

49:35Yes, and billions of dollars ride on some of these studies.

49:41And lives, right, not to mention.

49:44Right, but it would be easy to have full time statisticians

49:49hired by the journals or shared by the journals

49:55who were independent of any other financial incentive

50:00to go over these kind of methodological issues

50:04and take responsibility for certifying the analyses

50:08that are done and then pass it on

50:11to the volunteer peer reviewers.

50:14See, I believe even in this,

50:15in the sort of capitalism or even social capital,

50:19after watching Twitter in the time of COVID

50:23and just looking at people that investigate themselves,

50:27I believe in the citizenry.

50:30People, if you give them access to the data,

50:32like these like citizen scientists arise.

50:35A lot of them on the, it's kind of funny,

50:39a lot of people that are just really used

50:40to working with data,

50:43they don't know anything about medicine

50:44and they don't have actually the biases

50:46that a lot of doctors and medical

50:48and a lot of the people that read these papers,

§06Transcript · 50:51–1:01:03

50:51they'll just go raw into the data

50:53and look at it with like they're bored almost

50:56and they do incredible analysis.

50:58So I, you know, there's some argument to be made

51:01for a lot of this data to become public,

51:04like deanonymized, no, sorry, anonymized,

51:08all that kind of stuff, but for a lot of it to be public,

51:11especially when you're talking about things

51:14as impactful as some of these drugs.

51:16I agree 100%, so let's turn the micro,

51:19let's get a little bit more granular.

51:22On the peer review issue,

51:24we're talking about pre publication transparencies

51:27and that is critically important.

51:29Once a paper is published, the horses are out of the barn

51:33and docs are gonna read it,

51:34take it as evidence based medicine.

51:36The economists call what then happens as stickiness

51:41that the docs hold on to their beliefs

51:43and my own voice inside says,

51:47once doctors start doing things to their patients bodies,

51:52they're really not too enthusiastic

51:53about hearing it was wrong.

51:55Yeah, that's the stickiness of human nature.

51:57Wow, so that bar, once it's published,

52:01the doctors, that's when the stickiness emerges, wow.

52:05Yeah, it's hard to put that toothpaste back in the tube.

52:08Now, that's pre publication transparency,

52:11which is essential and you could have,

52:14whoever saw that data pre publication

52:17could sign confidentiality agreements

52:19so that the drug companies couldn't argue

52:22that we're just opening the spigots of our data

52:24and people can copy it and blah, all the excuses they make.

52:28You could argue that you didn't have to

52:30but let's just let them do it.

52:32Let the peer reviewers sign confidentiality agreements

52:35and they won't leak the data

52:36but then you have to go to post publication transparency,

52:39which is what you were just getting at

52:41to let the data free and let citizens

52:47and citizen scientists and other doctors

52:50who are interested have at it.

52:53Kind of like Wiki, Wikipedia, have at it.

52:57Let it out and let people criticize each other.

53:01Okay, so speaking of the data,

53:03the FDA asked 55 years to release Pfizer vaccine data.

53:08This is also something I raised with Albert Bourla.

53:11What did he say?

53:13There's several things I didn't like about what he said.

53:16So some things are expected

53:17and some of it is just revealing the human being,

53:20which is what I'm interested in doing.

53:23But he said he wasn't aware of the 75 and the 55.

53:27I'm sorry, wait a minute.

53:29He wasn't aware of?

53:30The how long, so here I'll explain what he.

53:33Do you know that since you spoke to him,

53:36Pfizer has petitioned the judge to join the suit

53:42in behalf of the FDA's request

53:45to release that data over 55 or 75 years?

53:50Pfizer's fully aware of what's going on.

53:52He's aware.

53:53I'm sure he's aware in some formulation.

53:56The exact years he might have not been aware.

53:59But the point is that there is,

54:02that is the FDA, the relationship of Pfizer and the FDA

54:06in terms of me being able to read human beings

54:11was the thing he was most uncomfortable with,

54:14that he didn't wanna talk about the FDA.

54:17And that really, it was clear

54:20that there was a relationship there

54:22that if the words you use may do a lot of harm,

54:26potentially because like you're saying,

54:28there might be lawsuits going on, there's litigation,

54:31there's legal stuff, all that kind of stuff.

54:33And then there's a lot of games being played in this space.

54:36So I don't know how to interpret it

54:40if he's actually aware or not,

54:41but the deeper truth is that he's deeply uncomfortable

54:49bringing light to this part of the game.

54:53Yes, and I'm gonna read between the lines

54:56and Albert Borla certainly didn't ask me to speak for him.

54:59But I think, but when did you speak to him?

55:02How long ago?

55:03Wow, time flies when you're having fun.

55:05Two months ago.

55:06Two months ago.

55:07So that was just recently it's come out,

55:12just in the past week it's come out

55:14that Pfizer isn't battling the FDA.

55:18Pfizer has joined the FDA in the opposition to the request

55:24to release these documents in the same amount of time

55:29that the FDA took to evaluate them.

55:33Yeah.

55:34So Pfizer is offering to help the FDA

55:43to petition the judge to not enforce the timeline

55:51that he seems to be moving towards.

55:54So for people who are not familiar,

55:55we're talking about the Freedom of Information Act request

55:59to release the Pfizer vaccine data, study data

56:05to release as much of the data as possible,

56:07like the raw data, the details,

56:08or actually not even the raw data,

56:10it's data, doesn't matter, there's details to it.

56:14And I think the response from the FDA is that of course,

56:20yes, of course, but we can only publish

56:25we can only publish like some X number of pages a day.

56:29500 pages.

56:31500 pages of data.

56:32It's not a day though, it's a week I think.

56:36The point is whatever they're able to publish is ridiculous.

56:39It's like my printer can only print three pages a day

56:45and we cannot afford a second printer.

56:48So it's some kind of bureaucratic language for,

56:52there's a process to this, and now you're saying

56:56that Pfizer is obviously more engaged

57:00in helping this kind of bureaucratic process prosper

57:04in its full absurdity, Kafkaesque absurdity.

57:08So what is this?

57:11This really bothered people.

57:13This really.

57:14This is really troublesome.

57:15And just to put it in just plain English terms,

57:19Pfizer's making the case that it can't,

57:24the FDA and Pfizer together are making the case

57:27that they can't go through the documents.

57:29It's gonna take them some number of hundredfold,

57:33hundreds of folds more time to go through the documents

57:37than the FDA required to go through the documents

57:39to approve the vaccines,

57:42to give the vaccines full FDA approval.

57:44And the FDA's argument, talk about Kafkaesque,

57:48is that to do it more rapidly

57:51would cost them $3 million.

57:54$3 million equals one hour of vaccine sales over two years.

58:01One hour of sales.

58:04And they can't come up with the money.

58:05And now Pfizer has joined the suit

58:08to help the FDA fight off this judge, this mean judge,

58:11who thinks they ought to release the data.

58:12But evidently Pfizer isn't offering

58:15to come up with the $3 million either.

58:17So, but for $3 million, I mean, maybe,

58:21maybe the FDA should do a GoFundMe campaign.

58:25Well, obviously the money thing,

58:28I mean, I'm sure if Elon Musk comes along and says,

58:31I'll give you $100 million, publish it now,

58:35I think they'll come up with another.

58:37So, I mean, it's clear that there's cautiousness.

58:43I don't know the source of it from the FDA.

58:47There's only one explanation that I can think of,

58:50which is that the FDA and Pfizer

58:53don't wanna release the data.

58:55They don't wanna release the three

58:57or 500,000 pages of documents.

59:03And I don't know what's in there.

59:05I wanna say one thing very clearly.

59:08I am not an anti faxer.

59:10I believe the vaccines work.

59:11I believe everybody should get vaccinated.

59:15The evidence is clear that if you're vaccinated,

59:17you reduce your risk of dying of COVID by 20 fold.

59:20And we've got new sub variants coming along.

59:23And I just wanna be very clear about this.

59:26That said, there's something I would give you 10 to one odds

59:32on a bet that there's something in that data

59:35that is gonna be embarrassing to either FDA or Pfizer

59:40or both.

59:41So there's two options.

59:42I agree with you 100%.

59:43One is they know of embarrassing things.

59:46That's option one.

59:48And option two, they haven't invested enough

59:51to truly understand the data.

59:54Like, I mean, it's a lot of data

59:56that they have a sense

59:58that might be something embarrassing in there.

60:00And if we release it,

60:02surely the world will discover the embarrassing

60:04and to do a sort of the steel man their argument.

60:08They'll take the small, the press,

60:11the people will take the small embarrassing things

60:14and blow them up into big things.

60:16Yes, and support the anti vax campaign.

60:20I think that's all possible.

60:22Nonetheless, the data are about the original clinical trial.

60:27And the emergency use authorization was based

60:33on the first few months of the data from that trial.

60:36And it was a two year trial.

60:37The rest of that data has not been opened up

60:40and there was not an advisory committee meeting

60:43to look at that data

60:44when the FDA granted full authorization.

60:47Again, I am pro vaccine.

60:49I am not making an anti vax argument here.

60:52But I suspect that there's something pretty serious

60:56in that data.

60:57And the reason why I'm not an anti vaxxer,

61:00having not been able to see the data

§07Transcript · 1:01:03–1:12:10

61:03that the FDA and Pfizer seem to willing

61:06not just to put effort into preventing the release of,

61:09but seem to have quite a bit of energy

61:12into preventing, invest quite a bit of energy

61:15in not releasing that data.

61:16The reason why that doesn't tip me over

61:18into the anti vaxxer side

61:20is because that's clinical trial data,

61:22early clinical trial data

61:23that involved several thousand people.

61:25We now have millions of data points

61:28from people who have had the vaccine.

61:31This is real world data,

61:32showing the efficacy of the vaccines.

61:35And so far, knock on wood,

61:38there aren't side effects

61:41that overcome the benefits of vaccine.

61:45So I'm with you.

61:46I'm now, I guess, three shots of the vaccine.

61:53But there's a lot of people that are kind of saying,

61:55well, even the data on the real world use large scale data

62:03is messy.

62:05The way it's being reported,

62:06the way it's being interpreted.

62:08Well, one thing is clear to me

62:11that it is being politicized.

62:13I mean, if you just look objectively,

62:17don't have to go to at the shallow surface level.

62:21It seems like there's two groups

62:25that I can't even put a term to it

62:29because it's not really pro vaccine versus anti vaccine

62:32because it's pro vaccine, triple mask, Democrat, liberal,

62:41and then anti mandate, whatever those groups are.

62:44I can't quite, cause they're changing.

62:46Anti mask, but not really, but kind of.

62:50So those two groups that feel political in nature,

62:53not scientific in nature, they're bickering.

62:56And then it's clear that this data is being interpreted

63:01by the different groups differently.

63:04And it's very difficult for me as a human being

63:07to understand where the truth lies,

63:11especially given how much money is flying around

63:14on all sides.

63:15So the anti vaxxers can make a lot of money too.

63:19Let's not forget this.

63:20From the individual perspective,

63:22you can become famous being an anti vaxxer.

63:25And so there's a lot of incentives on all sides here.

63:28And there's real human emotion and fear

63:33and also credibility.

63:37Scientists don't wanna ruin their reputation

63:41if they speak out in whatever, like speak their opinion

63:45or they look at some slice of the data

63:49and begin to interpret it in some kind of way.

63:51They're very, it's clear that fear is dominating

63:53the discourse here, especially in the scientific community.

63:57So I don't know what to make of that.

64:01And the only happy people here is Pfizer.

64:06It's just plowing all ahead.

64:08I mean, with every single variant,

64:13there's very, I would say, outside of arguably

64:20a very flawed system, there's a lot of incredible

64:23scientific and engineering work being done

64:25in constantly developing new, like antiviral drugs,

64:29new vaccines to deal with the variants.

64:33So they're happily being a capitalist machine.

64:37And it's very difficult to know what to do with that.

64:43And let's just put this in perspective for folks.

64:46The best selling drug in the world has been Humira

64:49for a number of years.

64:51It's approved for the treatment of rheumatoid arthritis

64:55and eight other indications.

64:57And it's sold about $20 billion globally

65:02over the past few years.

65:03It peaked at that level.

65:07Pfizer expects to sell $65 billion of vaccine

65:12in the first two years of the pandemic.

65:16So this is by far the biggest selling

65:19and most profitable drug that's ever come along.

65:22I can ask you a difficult question here.

65:28In the fog that we're operating in here,

65:34on the Pfizer BioNTech vaccine,

65:40what was done well and what was done badly

65:43that you can see now, it seems like we'll know

65:47more decades from now.

65:50Yes.

65:51But now in the fog of today with the $65 billion

65:57flying around, where do you land?

66:03So we're gonna get to what I think is one of the key problems

66:08with the pharmaceutical industry model in the United States

66:12about being profit driven.

66:15So in 2016, the NIH did the key infrastructure work

66:22to make mRNA vaccines.

66:26That gets left out of the discussion a lot.

66:29And Pfizer BioNTech actually paid royalties voluntarily

66:35to the NIH.

66:36I don't know how much it was.

66:36I don't think it was a whole lot of money,

66:38but I think they wanted to avoid the litigation

66:41that Moderna got itself into by just taking that 2016

66:45knowledge and having that be the foundation

66:48of their product.

66:50So Pfizer took that and they did their R&D,

66:54they paid for their R&D having received that technology.

66:59And when they got the genetic code from China

67:03about the virus, they very quickly made a vaccine

67:09and the vaccine works.

67:10And President Trump to his credit launched

67:14Operation Warp Speed and just threw money at the problem.

67:18They just said, we spent five times more per person

67:22than the EU early on, just pay them whatever they want.

67:26Let's just get this going.

67:28And Americans were vaccinated more quickly.

67:32We paid a lot of money.

67:34The one mistake that I think the federal government made

67:37was they were paying these guaranteed fortunes

67:41and they didn't require that the companies participate

67:45in a program to do global vaccinations.

67:50So the companies doing their business model

67:53distributed the vaccines where they would make

67:56the most money.

67:57And obviously they would make the most money

67:59in the first world.

68:00And almost I think 85% of the vaccines early on

68:04went to the first world and very, very few vaccinations

68:08went to the third world.

68:10So what happened is there was such a low vaccination rate

68:16in May of 2021, there was all hands on deck cry for help

68:23from the World Trade Organization,

68:26the World Health Organization, the IMF and the World Bank

68:31made a plea for $50 billion so that we could get

68:36to 40% vaccination rate in the third world

68:40by the end of 2021.

68:44And it was unrequited, nobody answered.

68:48And now Africa has about a 8.9% vaccination rate.

68:54India is coming up, but it's been very low.

68:57The problem with all this is I believe those mRNA vaccines

69:02are excellent vaccines.

69:04But if we leave the third world unvaccinated,

69:07we're gonna have a constant supply of variants of COVID

69:12that are gonna come back into the United States

69:15and harm Americans exactly like Delta and Omicron have.

69:20So we've made a great drug, it reduces the risk of mortality

69:25in Americans who get it by a lot.

69:28But we're not doing what we need to do

69:31to protect Americans from Omicron.

69:33You don't have to be an idealist

69:34and worry about global vaccine equity.

69:36If you're just ordinary selfish people like most of us are,

69:41and you're worried about the health of Americans,

69:43you would ensure global vaccine distribution.

69:47Let me just make one more point.

69:49That $50 billion that was requested

69:51by the four organizations back in May of 2021,

69:5532 billionaires made $50 billion

69:59from the vaccines at that point,

70:01took it into their private wealth.

70:03So what had been taken,

70:05this enormous amounts of money that had been taken

70:06into private wealth was enough to do

70:10what those organizations said needed to be done

70:12to prevent the sub variants from coming back

70:15and doing what they're doing.

70:16So the money was there, but how does the motivation,

70:19the money driven motivation of Big Pharma lead to that,

70:22that kind of allocation of vaccines?

70:28Because they can make more money in the United States.

70:31They're gonna distribute their vaccines

70:33where they can make the most money.

70:34Right, is there a malevolent aspect to this

70:40where, boy, I don't like saying this,

70:44but that they don't see it as a huge problem

70:49that variants will come back to the United States.

70:53I think it's the issue we were talking about earlier on

70:56where they're in a different culture

70:58and their culture is that their moral obligation,

71:02as Milton Friedman would say,

71:04is to maximize the profits

71:06that they return to shareholders.

71:07And don't think about the bigger picture.

71:10The collateral damage, don't think about the collateral.

71:12And also kind of believe, convince yourself

71:16that if we give into this capitalist machine

71:20in this very narrow sense of capitalism,

71:23that in the end, they'll do the most good.

71:25This kind of belief that like,

71:28if we just maximize profits, we'll do the most good.

71:32Yeah, that's an orthodoxy of several decades ago.

71:36And I don't think people can really say that in good faith.

71:40When you're talking about vaccinating the third world

71:43so we don't get hurt,

71:44it's a little bit hard to make the argument

71:47that the world's a better place

71:48because the profits of the investors went up.

71:51Yeah, but at the same time,

71:54I think that's a belief you can hold.

71:58I mean, I've interacted with a bunch of folks that kinda,

72:01it's the, I don't wanna mischaracterize Ayn Rand, okay?

72:05I respect a lot of people,

72:07but there's a belief that can take hold.

§08Transcript · 1:12:10–1:22:51

72:10If I just focus on this particular maximization,

72:13it will do the most good for the world.

72:16The problem is when you choose what to maximize

72:19and you put blinders on,

72:20it's too easy to start making gigantic mistakes

72:24that have a big negative impact on society.

72:28So it's really matters what you're maximizing.

72:30Right, and if we had a true democracy

72:33and everybody had one vote,

72:36everybody got decent information and had one vote,

72:39Ayn Rand's position would get some votes, but not many,

72:44and it would be way outvoted by the common people.

72:48Let me ask you about this very difficult topic.

72:53I'm talking to Mark Zuckerberg of Metta,

73:00the topic of censorship.

73:03I don't know if you've heard,

73:04but there's a guy named Robert Malone and Peter McCullough

73:08that were removed from many platforms

73:10for speaking about the COVID vaccine as being risky.

73:14They were both on Joe Rogan's program.

73:17What do you think about censorship in this space?

73:23In this difficult space where so much is controlled by,

73:29not controlled, but influenced by advertisements

73:31from Big Pharma,

73:32and science can even be influenced by Big Pharma.

73:39Where do you lean on this?

73:41Should we lean towards freedom

73:46and just allow all the voices,

73:50even those that go against the scientific consensus?

73:54Is that one way to fight the science

73:59that is funded by Big Pharma,

74:02or is that do more harm than good,

74:05having too many voices that are contending here?

74:08Should the ultimate battle be fought

74:10in the space of scientific publications?

74:15And particularly in the era of COVID,

74:19where there are large public health ramifications

74:22to this public discourse, the ante is way up.

74:27So I don't have a simple answer to that.

74:31I think everyone's allowed their own opinion.

74:34I don't think everyone's allowed their own scientific facts.

74:38And how we develop a mechanism

74:43that's other than an open internet

74:45where whoever is shouting the loudest gets the most clicks

74:49and rage creates value on the internet,

74:54I think that's not a good mechanism for working this out.

74:58And I don't think we have one.

74:59I don't have a solution to this.

75:01I mean, ideally, if we had a philosopher king,

75:05we could have a panel of people

75:08who were not conflicted by rigid opinions

75:13decide on what the boundaries of public discourse might be.

75:19I don't think it should be fully open.

75:21I don't think people who are making,

75:25who are committed to an anti vaccine position

75:28and will tailor their interpretation

75:31of complex scientific data to support their opinion,

75:34I think that can be harmful.

75:36Constraining their speech can be harmful as well.

75:39So I don't have an answer here.

75:41But yeah.

75:42I tend to believe that it's more dangerous

75:45to censor anti vax messages.

75:49The way to defeat anti vax messages

75:53is by being great communicators,

75:56by being great scientific communicators.

75:58So it's not that we need to censor

76:02the things we don't like.

76:04We need to be better at communicating

76:06the things we do like,

76:08or the things that we do believe represent

76:10the deep scientific truth.

76:13Because I think if you censor,

76:18you get worse at doing science

76:22and you give the wrong people power.

76:27So I tend to believe that you should give power

76:30to the individual scientists

76:33and also give them the responsibility

76:35of being better educators, communicators,

76:38expressers of scientific ideas,

76:41put pressure on them to release data,

76:43to release that data in a way that's easily consumable,

76:46not just like very difficult to understand,

76:49but in a way that can be understood

76:50by a large number of people.

76:52So the battle should be fought

76:54in the open space of ideas

76:57versus in the quiet space of journals.

77:02I think we no longer have that comfort,

77:05especially at the highest of stakes.

77:08So this kind of idea that a couple of peer reviewers

77:11decide the fate of billions

77:14doesn't seem to be sustainable,

77:18especially given a very real observation now

77:24that the reason Robert Malone has a large following

77:30is there's a deep distrust of institutions,

77:33deep distrust of scientists,

77:34of science as an institution,

77:37of power centers, of companies, of everything,

77:41and perhaps rightfully so.

77:43But the way to defend against that

77:45is not for the powerful to build a bigger wall.

77:49It's for the powerful to be authentic

77:53and maybe a lot of them to get fired,

77:55and for new minds, for new fresh scientists,

77:59ones who are more authentic, more real,

78:01better communicators to step up.

78:03So I fear censorship

78:06because it feels like censorship

78:09is an even harder job to do it well

78:13than being good communicators.

78:16And it seems like it's always the C students

78:19that end up doing the censorship.

78:21It's always the incompetent people,

78:24and not just the incompetent, but the biggest whiners.

78:28So what happens is the people

78:32that get the most emotional and the most outraged

78:36will drive the censorship.

78:39And it doesn't seem like reason drives the censorship.

78:42That's just objectively observing

78:44how censorship seems to work in this current.

78:47So there's so many forms of censorship.

78:50You look at the Soviet Union

78:51or the propaganda or Nazi Germany,

78:54it's a very different level of censorship.

78:56People tend to conflate all of these things together.

78:59Social media trying desperately to have trillions

79:03or hundreds of billions of exchanges a day,

79:07and try to make sure that their platform

79:10has some semblance of, quote, healthy conversations.

79:16People just don't go insane.

79:18They actually like using the platform,

79:20and they censor based on that.

79:23That's a different level of censorship.

79:24But even there, you can really run afoul

79:28of the people that get the whiny C students

79:32controlling too much of the censorship.

79:34I believe you should actually put the responsibility

79:39on the self proclaimed holders of truth,

79:42AKA scientists, at being better communicators.

79:46I agree with that.

79:47I'm not advocating for any kind of censorship.

79:51But Marshall McLuhan was very influential

79:55when I was in college.

79:57And his, that meme, the medium is the message.

80:03It's a little bit hard to understand

80:04when you're comparing radio to TV

80:06and saying radio's hotter or TV's hotter or something.

80:09But we now have the medium as the message

80:12in a way that we've never seen,

80:14we've never imagined before,

80:16where rage and anger and polarization

80:22are what drives the traffic on the internet.

80:28And we don't, it's a question of building the commons.

80:34Ideally, I don't know how to get there,

80:36so I'm not pretending to have a solution.

80:38But the commons of discourse about this particular issue,

80:42about vaccines, has been largely destroyed by the edges,

80:47by the drug companies and the advocates on the one side

80:50and the people who just criticize and think

80:54that even though the data are flawed

80:57that there's no way vaccines can be beneficial.

81:00And to have those people screaming at each other

81:04does nothing to improve the health

81:07of the 95% of the people in the middle

81:10who want to know what the rational way to go forward is

81:16and protect their families from COVID

81:18and live a good life

81:20and be able to participate in the economy.

81:22And that's the problem.

81:25I don't have a solution.

81:26Well, there's a difficult problem for Spotify and YouTube.

81:29I don't know if you heard,

81:30this is a thing that Joe Rogan is currently going through.

81:33As a platform, whether to censor the conversation

81:36that, for example, Joe's having.

81:39So I don't know if you heard,

81:40but Neil Young and other musicians have kind of spoke out

81:43and saying they're going to leave the platform

81:45because Joe Rogan is allowed to be on this platform

81:49having these kinds of conversations

81:51with the likes of Robert Malone.

81:54And it's clear to me that Spotify and YouTube

81:57are being significantly influenced

81:59by these extreme voices, like you mentioned, on each side.

82:03And it's also clear to me that Facebook is the same

82:05and it was going back and forth.

82:07In fact, that's why Facebook has been oscillating

82:10on the censorship is like one group gets louder

82:12than the other, depending on whether it's an election year.

82:19There's several things to say here.

82:21So one, it does seem, I think you put it really well,

82:24it would be amazing if these platforms

82:26could find mechanisms to listen to the center,

82:29to the big center that's actually going to be affected

82:34by the results of our pursuit of scientific truth.

82:40And listen to those voices.

82:42I also believe that most people are intelligent enough

82:45to process information and to make up their own minds.

82:49Like they're not, in terms of,

§09Transcript · 1:22:54–1:32:12

82:54it's complicated, of course,

82:55because we've just been talking about advertisement

82:57and how people can be influenced.

82:58But I feel like if you have raw, long form podcasts

83:05or programs where people express their mind

83:08and express their argument in full,

83:12I think people can hear it to make up their own mind.

83:15And if those arguments have a platform on which

83:18they can live, then other people could provide

83:21better arguments if they disagree with it.

83:23And now we as human beings, as rational,

83:26as intelligent human beings, can look at both

83:29and make up our own minds.

83:30And that's where social media can be very good

83:33at this collective intelligence.

83:35We together listen to all of these voices

83:39and make up our own mind.

83:40Humble ourselves, actually, often.

83:42You think, you know, like you're an expert,

83:46say you have a PhD in a certain thing,

83:48so there's this confidence that comes with that.

83:50And the collective intelligence, uncensored,

83:54allows you to humble yourself eventually.

83:56Like as you discover, all it takes is a few times,

84:01you know, looking back five years later,

84:05realizing I was wrong.

84:07And that's really healthy for a scientist.

84:09That's really healthy for anybody to go through.

84:11And only through having that open discourse

84:13can you really have that.

84:15That said, Spotify also, just like Pfizer is a company,

84:20which is why this podcast,

84:26I don't know if you know what RSS feeds are,

84:29but podcasts can't be censored.

84:31So Joe's in the unfortunate position

84:33he only lives on Spotify.

84:35So Spotify has been actually very good

84:37at saying we're staying out of it for now.

84:41But RSS, this is pirate radio.

84:44Nobody can censor it, it's the internet.

84:47So financially, in terms of platforms,

84:51this cannot be censored,

84:53which is why podcasts are really beautiful.

84:56And so if Spotify or YouTube wants to be

85:01the host of podcasts,

85:04I think where they flourish is free expression,

85:10no matter how crazy.

85:12Yes, but I do wanna push back a little bit on what you're saying.

85:18I have anti fax friends who I love.

85:23They're dear, cherished friends.

85:26And they'll send me stuff.

85:28And it'll take me an hour to go through what they sent

85:34to see if it is credible.

85:37And usually it's not.

85:40It's not a random sample of the anti fax argument.

85:42I'm not saying I can disprove the anti fax argument.

85:46But I am saying that it's almost like we were talking about

85:50how medical science clinical trials,

85:54the presentation of clinical trials to physicians

85:56could be improved.

85:57And the first thing we came up with

86:00is to have pre publication transparency

86:04in the peer review process.

86:06So bad information, biased information doesn't get out

86:10as if it's legitimate, and you can't put it back,

86:13recapture it once it gets out.

86:16I think there's an element of that

86:18in the arguments that are going on about vaccines.

86:21And they're on both sides.

86:23But I think the anti fax side puts out more units

86:28of information claiming to show that the vaccines don't work.

86:33And I guess in an ideal situation,

86:36there would be real time fact checking by independent people,

86:41not to censor it, but to just say that study was set up

86:45to do this, and this is what the conclusions were.

86:47So the way it was stated is on one side of this argument.

86:52But that's what I'm arguing.

86:53I agree with you.

86:55What I'm arguing is that this big network of humans

86:58that we have, that is the collective intelligence,

87:00can't do that real time if you allow it to,

87:04if you encourage people to do it.

87:05And the scientists, as opposed to, listen,

87:08I interact with a lot of colleagues,

87:10a lot of friends that are scientists,

87:12they roll their eyes.

87:14Their response is like, ugh.

87:16Like they don't want to interact with this.

87:18But that's just not the right response.

87:22When a huge number of people believe this,

87:26it is your job as communicators to defend your ideas.

87:30It is no longer the case that you go to a conference

87:33and defend your ideas to two other nerds

87:36that have been working on the same problem forever.

87:38I mean, sure, you can do that,

87:40but then you're rejecting the responsibility

87:44you have explicitly or implicitly accepted

87:48when you go into this field,

87:49that you will defend the ideas of truth.

87:52And the way to defend them is in the open battlefield

87:55of ideas, and become a better communicator.

87:58And I believe that when you have a lot,

88:00you said you invested one or two hours

88:02in this particular, but that's little ants interacting

88:06at scale, I think that allows us to progress towards truth.

88:12At least, you know, at least I hope so.

88:14I think you're an optimist.

88:15I want to work with you a little bit on this.

88:17Let's say a person like Joe Rogan,

88:22who, by the way, had me on his podcast and let me.

88:26It's an amazing conversation, I really enjoyed it.

88:28Well, thank you.

88:29I did too.

88:29And I didn't know Joe.

88:31I didn't know much about his podcast.

88:32He pushed back on Joe a bunch, which is great.

88:35And he was a gentleman, and we had it out.

88:38In fact, he put one clip, at one point,

88:41he said something that was a little bit wrong,

88:43and I corrected him.

88:44And he had the guy who.

88:46Jamie.

88:47Jamie, he had Jamie check it,

88:48and was very forthright in saying,

88:51yeah, you know, John's got a right here.

88:53We gotta modify this.

88:54In any event, in any event.

88:56You got him.

88:58Well, I wasn't trying to get him,

88:59I was just trying to. No, no, no, no.

89:01Totally, it was a beautiful exchange.

89:03There was so much respect in the room,

89:04pushing back and forth, it was great.

89:06Yeah, so I respect him.

89:08And I think when he has somebody on

89:13who's a dyed in the wool anti faxer,

89:16the question is, how can you balance,

89:21if it needs balance, in real time?

89:24I'm not talking about afterwards.

89:26I'm talking in real time.

89:27Maybe you record, well, he does record it, obviously.

89:30But maybe when there's a statement made

89:33that is made as if it's fact based,

89:38maybe that statement should be checked by

89:41some folks who,

89:45imaginary folks who are trustworthy.

89:48And in real time, as that discussion

89:51is being played on the podcast,

89:54to show what independent experts say about that claim.

89:59That's a really interesting idea.

90:00By the way, for some reason,

90:01this idea popped into my head now.

90:03I think real time is very difficult,

90:05and it's not difficult,

90:07but it kind of ruins the conversation

90:09because you want the idea to breathe.

90:11I think what's very possible is before it's published,

90:15it's the pre publication, before it's published,

90:18you let a bunch of people review it,

90:20and they can add their voices in post.

90:23Before it's published, they can add arguments,

90:29arguments against certain parts.

90:31That's very interesting to sort of,

90:32as one podcast, publish addendums.

90:37Publish the peer review together with the publication.

90:40That's very interesting.

90:43I might actually do that.

90:44That's really interesting.

90:45Because I've been doing more debates

90:47where at the same time have multiple people,

90:51which has a different dynamic

90:53because both people, I mean,

90:56it's really nice to have the time to pause

90:58just by yourself to fact check,

91:02to look at the study that was mentioned,

91:04to understand what's going on.

91:05So the peer review process, to have a little bit of time.

91:09That's really interesting.

91:10I actually would, I'd like to try that.

91:14To agree with you on some point in terms of anti vax,

91:17I've been fascinated by listening to arguments

91:20from this community of folks that's been quite large

91:23called the flat earthers,

91:25the people that believe the earth is flat.

91:28And I don't know if you've ever listened to them

91:30or read their arguments,

91:33but it's fascinating how consistent

91:36and convincing it all sounds

91:37when you just kind of take it in.

91:39Just like, just take it in like listening normally.

91:43It's all very logical.

91:46Like if you don't think very,

91:49well, no, so the thing is,

91:53the reality is at the very basic human level

91:57with our limited cognitive capabilities,

92:00the earth is pretty flat when you go outside

92:03and you look at flat.

92:04So like when you use common sense reasoning,

92:08it's very easy to play to that,

92:09to convince you that the earth is flat.

§10Transcript · 1:32:12–1:41:45

92:12Plus there's powerful organizations

92:13that want to manipulate you and so on.

92:16But then there's the whole progress of science

92:20and physics of the past,

92:22but that's difficult to integrate into your thought process.

92:26So it's very true that the people

92:29should listen to flat earthers

92:30because it was very revealing to me

92:33how easy it is to be convinced of basically anything

92:39by charismatic arguments.

92:42And if we're arguing about whether the earth is flat or not,

92:46as long as we're not navigating airplanes

92:48and doing other kinds of things,

92:49trying to get satellites to do transmission,

92:53it's not that important what I believe.

92:56But if we're arguing about how we approach

92:59the worst public health crisis in,

93:02I don't know how long,

93:03I think we're getting worse than the Spanish flu now.

93:06I don't know what the total global deaths

93:07with Spanish flu were, but in the United States,

93:10we certainly have more deaths than we had from Spanish flu.

93:12Plus the economic pain and suffering.

93:14Yes, yes, and the damage to the kids in school and so forth.

93:19We got a problem and it's not going away, unfortunately.

93:23So when we get a problem like that,

93:25it's not just an interesting bar room conversation

93:28about whether the earth is flat.

93:30There are millions of lives involved.

93:34Let me ask you yet another question,

93:36an issue I raised with Pfizer CO, Albert Burla.

93:42It's the question of revolving doors.

93:45That there seems to be a revolving door

93:47between Pfizer, FDA, and CDC.

93:51People that have worked at the FDA,

93:53now work at Pfizer, and vice versa,

93:56including the CDC and so on.

94:00What do you think about that?

94:01So first of all, his response, once again,

94:03is there's rules, there's very strict rules,

94:06and we follow them.

94:08Do you think that's a problem?

94:11Hoo ha.

94:12And also, maybe this is a good time to talk about

94:16this Pfizer play by the rules.

94:19One at a time?

94:20One at a time.

94:21Okay, and this isn't even about Pfizer,

94:22but it's an answer to the question.

94:24Yes.

94:25So there's this drug, Ajihelm,

94:27that was approved by the FDA maybe six months ago.

94:31It's a drug to prevent the progression

94:34of low grade Alzheimer's disease.

94:38The target for drug development for Alzheimer's disease

94:43has been reducing the amyloid plaques in the brain,

94:47which correlate with the progression of Alzheimer's.

94:52And Biogen showed that its drug, Ajihelm,

94:57reduces amyloid plaques in the brain.

95:00They did two clinical trials

95:03to determine the clinical efficacy,

95:05and they found that neither trial showed a meaningful benefit.

95:09And in those two trials,

95:1233% more people in the Ajihelm group

95:15developed symptomatic brain swelling and bleeding

95:19than people in the placebo group.

95:22There was an advisory committee convened

95:27to debate and determine how they felt

95:30about the approvability of Ajihelm, given those facts.

95:35And those facts aren't in dispute.

95:37They're in Biogen slides, as well as FDA documents.

95:41The advisory committee voted 10 against approval

95:47and one abstain.

95:49So that's essentially universal,

95:52unanimous vote against approving Ajihelm.

95:56Now, the advisory committees have been pretty much cleansed

96:00of financial conflicts of interest.

96:03So this advisory committee votes 10 no, one abstention,

96:09and the FDA overrules the unanimous opinion

96:13of its advisory committee and approves the drug.

96:17Three of the members of the advisory committee resign.

96:21They say, we're not gonna be part,

96:22if the FDA is not gonna listen to a unanimous vote

96:24against approving this drug,

96:26which shows more harm than benefit, undisputed,

96:31we're not gonna participate in this.

96:33And the argument against approval

96:36is that the surrogate endpoint,

96:38the reduction of amyloid, the progression of amyloid plaques

96:43is known by the FDA not to be a valid clinical indicator.

96:48It doesn't correlate, 27 studies have shown,

96:50it doesn't correlate with clinical progression,

96:53interrupting the amyloid plaques

96:54doesn't mean that your Alzheimer's doesn't get worse.

97:02So it seems like it's a slam dunk

97:05and the FDA made a mistake and they should do whatever

97:09they do to protect their bureaucratic reputation.

97:12So the head of the Bureau of the FDA,

97:15the Center for Drug Evaluation and Research

97:17that approves new drugs, who had spent 16 years

97:21as an executive in the pharmaceutical industry,

97:25issued a statement and said,

97:28"'What we should do in this situation

97:30"'is to loosen the prohibition of financial ties of interest

97:36"'with the drug companies,

97:38"'so we get less emotional responses.'"

97:43Said this, it's in print.

97:49People are just too emotional about this.

97:51People were just too emotional.

97:52The 10 people who voted against it

97:55and the no people who voted for it,

97:56it's all too emotional.

97:58So this gets back,

98:00this is a long answer to your short question.

98:02I think this is a wonderful window

98:04into the thinking of the FDA

98:08that financial conflicts of interest don't matter

98:11in a situation when I think it's obvious

98:13that they would matter.

98:15But there's not a direct financial conflict of interest.

98:18It's kinda, like it's not, like Albert said, there's rules.

98:26I mean, you're not allowed

98:27to have direct financial conflicts of interest.

98:29It's indirect.

98:32Right, but what I'm saying is,

98:34I'm not denying what he said is true,

98:37but the FDA, a high official in the FDA,

98:42is saying that we need to allow conflicts of interest

98:45in our advisory committee meetings.

98:48Wow.

98:49And that, she wants to change the rules.

98:53Right.

98:54So Albert Borla would still be playing by the rules,

98:58but it just shows how one side of the thinking here is.

99:03But you think that's influenced by the fact

99:05that there were pharmaceutical executives

99:07working at the FDA and vice versa?

99:09And they think that's a great idea.

99:13Who gets to fix this?

99:14Do you think it should be just banned?

99:16Like if you worked.

99:17I don't know, two separate questions.

99:19One is should the officials at the FDA come from pharma

99:23and vice versa?

99:24Yes.

99:25That's one question.

99:26And the other question is should advisory committee members

99:28be allowed to have financial conflicts of interest?

99:31Yes.

99:33I think, in my opinion, and people might say I'm biased,

99:38I think advisory committee people

99:40should not have conflicts of interest.

99:42I think their only interest ought to be the public interest.

99:44And that was true from my understanding of the situation.

99:49It's the afterword in my book.

99:51I spent some time studying it about Ajihelm.

99:54I think it's a slam dunk that there ought to be

99:56no conflicts of interest.

99:57Now the head of CDER, Center for Drug Evaluation Research,

100:01thinks that that's gonna give you a biased result

100:04because we don't have company influence.

100:07And that, I think, shows how biased their thinking is.

100:14That not having company influence is a bias.

100:19Let me try to load that in.

100:21I'm trying to empathize with the belief

100:23that companies should have a voice at the table.

100:28I mean, yeah, it's part of the game.

100:30They've convinced themselves

100:31that this is how it should be played.

100:34But they have a voice at the table.

100:36They've designed the studies.

100:37Right.

100:38That's their voice.

100:39That's the whole point.

100:40They analyze the data.

100:41I mean, what bigger voice do you deserve?

100:43But I do also think, on the more challenging question,

100:47I do think that there should be a ban.

100:50If you work at a pharmaceutical company,

100:53you should not be allowed to work

100:55at any regulatory agency.

101:00Yes.

101:01You should not.

101:02I mean, that, going back and forth,

101:03it just, even if it's 30 years later.

101:06Yeah, I agree.

101:07And I have another nomination for a ban.

101:11We're in this crazy situation

101:12where Medicare is not allowed to negotiate

101:15the price of drugs with the drug companies.

101:17So the drug companies get a patent on a new drug.

101:20Unlike every other developed country,

101:22they can charge whatever they want

101:24so they have a monopoly on a utility

101:27because no one else can make the drug.

101:29Charge whatever they want and Medicare has to pay for it.

101:31And you say, how did we get in this crazy situation?

101:36So how we got here is that in 2003,

101:39when Medicare Part D was passed,

101:42Billy Towson was head of the Ways and Means Committee

§11Transcript · 1:41:45–1:52:32

101:45in the House, played a key role in ushering this through

101:48with the nonnegotiation clause of it.

101:52And after it was passed,

101:53Billy Towson did not finish out his term in Congress.

101:57He went to pharma for a $2 million a year job.

102:02This is incredible.

102:05You might think that a ban on that would be a good idea.

102:09I spoke with Francis Collins, head of the NIH,

102:12on this podcast.

102:13He and NIH have a lot of power over funding in science.

102:22What are they doing right, what are they doing wrong

102:24in this interplay with big pharma?

102:28How connected are they?

102:32Again, returning to the question,

102:33what are they doing right,

102:35what are they doing wrong in your view?

102:37So my knowledge of the NIH is not as granular

102:41as my knowledge of pharma.

102:44That said, in broad brushstrokes,

102:47the NIH is doing the infrastructure work

102:51for all drug development.

102:53I think they've participated in 100% of the drugs

102:56that have been approved by the FDA

102:58over the past 10 years or so.

103:01They've done infrastructure work.

103:03And what they do is not work on particular drugs,

103:08but they develop work on drug targets,

103:12on targets in the human body that can be affected by drugs

103:16and might be beneficial to turn on or off.

103:21And then the drug companies, when they find a target

103:24that is mutable and potentially beneficial,

103:29then the drug companies can take the research

103:32and choose to invest in the development of the drugs,

103:34specific drug.

103:36That's our model.

103:38Now, 96% of the research that's done in clinical trials

103:44in the United States is about drugs and devices.

103:47And only a fraction of the 4% that's left over

103:49is about preventive medicine

103:51and how to make Americans healthier.

103:54I think, again, from the satellite view,

103:58the NIH is investing more in science

104:04that can lead to commercial development

104:07rather than, as you said at the beginning of the podcast,

104:10there's no big fitness and lifestyle industry

104:13that can counter pharma.

104:15So I think at the NIH level, that countering can be done.

104:19And the diabetes prevention program study

104:22that we talked about before where lifestyle

104:24was part of a randomized trial

104:26and was shown to be more effective than metformin

104:28at preventing the development of diabetes,

104:31that is absolute proof positive

104:34that investing in that kind of science

104:36can produce good results.

104:37So I think that we're aimed at drug development

104:43and what we ought to be aimed at

104:44is an epidemiological approach

104:47to improving the health of all Americans.

104:49We rank 68th in the world in healthy life expectancy

104:55despite spending an extra trillion and a half dollars a year.

104:59And I believe strongly

105:02that the reason why we've gotten in this crazy position

105:06is because the knowledge that we're producing

105:10is about new drugs and devices

105:12and it's not about improving population health.

105:15In this problem, the NIH is the perfect institution

105:19to play a role in rebalancing our research agenda.

105:23And some of that is on the leadership side

105:24with Francis Collins and Anthony Fauci,

105:27not just speaking about basically everything

105:32that just leads to drug development, vaccine development,

105:34but also speaking about healthy lifestyles

105:36and speaking about health, not just sickness.

105:40Yes, and investing, investing in health.

105:43I mean, it's like one feeds the other.

105:49One, you have to communicate to the public

105:51the importance of investing in health

105:53and that leads to you getting props for investing in health

105:57and then you can invest in health more and more

105:59and that communicates, I mean,

106:01everything that Anthony Fauci says or Francis Collins says

106:05has an impact on scientists.

106:07I mean, it sets the priorities.

106:12I don't think they, it's the sad thing about leaders,

106:18forgive me for saying the word, but mediocre leaders

106:22is they don't see themselves as part of a game.

106:26They don't see the momentum.

106:29It's like a fish in the water.

106:31They don't see the water.

106:32Great leaders stand up and reverse the direction

106:36of how things are going.

106:37And I actually put a lot of responsibility,

106:39some people say too much, but whatever.

106:43I think leaders carry the responsibility.

106:46I put a lot of responsibility on Anthony Fauci

106:48and Francis Collins for not actually speaking

106:51a lot more about health, not, and bigger,

106:55inspiring people in the power

107:01and the trustworthiness of science.

107:05You know, that's on the shoulders of Anthony Fauci.

107:12I'm gonna abstain from that

107:13because I'm not expert enough, but.

107:15Neither am I, but I'm opinionated.

107:18I am too, but not on camera.

107:21Yes.

107:22No, but seriously, the problem is pretty simple,

107:27that we're investing 96% of our funding

107:31of clinical research in drugs and devices

107:33and 80% of our health is determined

107:36by how we live our lives.

107:38Yes.

107:39And this is ridiculous.

107:42The United States is going further and further

107:45behind the other wealthy countries in terms of our health.

107:49We ranked 38th in healthy life expectancy in 2000

107:53and now we're spending a trillion and a half dollars extra

107:56and we rank 68th.

107:58We've gone down.

107:59You have this excellent, there's a few charts

108:02that I'll overlay that tell this story

108:06in really powerful ways.

108:09So one is the healthcare spending is percentage of GDP

108:13that on the X axis is years and the Y axis is percentage

108:17and the United States as compared to other countries

108:20on average has been much larger and growing.

108:26Right, we are now spending 7% more of our GDP,

108:3017.7% versus 10.7% on healthcare.

108:357% and I think GDP is the fairest way

108:38to compare healthcare spending.

108:40Where per person in dollars we're spending even,

108:43the difference is even greater

108:45but other costs vary with GDP.

108:48So let's stick with the conservative way to do it.

108:5017.7 or 18% of GDP, 18% of GDP spent on healthcare,

109:007% higher than the comparable country average.

109:04Right.

109:0517.7% versus 10.7, 7% higher.

109:09Right and 7% of $23 trillion GDP

109:15is more than $1.5 trillion a year in excess.

109:19And then you have another chart that shows

109:21healthcare system performance compared to spending.

109:25And there's a cloud, a point cloud of different countries.

109:29The X axis being healthcare spending

109:33is a percentage of GDP which we just talked about.

109:36That US is 7% higher than everyone, the average.

109:40And then on the Y axis is performance.

109:44So X axis spending, Y axis performance.

109:48And there's a point cloud, we'll overlay this

109:50if you're watching on YouTube,

109:52of a bunch of countries that have high performance

109:58for what they're spending and then US

110:02is all alone on the right bottom side of the chart

110:07where it's low performance and high spending.

110:10Correct.

110:12So this is a system that is abiding by spending

110:17that is directed by the most profitable ways

110:21to deliver healthcare.

110:22So you put that in the hands of big pharma.

110:25As you maximize for profit, you're going to decrease

110:28performance and increase spending.

110:31Yes, but I wanna qualify that and say

110:34it's not all big pharma's fault.

110:37They're not responsible for all the problems

110:39in our healthcare system.

110:41They're not responsible for the administrative costs

110:43for example.

110:44But they are the largest component of the rising,

110:49our rising healthcare costs.

110:51And it has to do with this knowledge issue.

110:54Controlling the knowledge that doctors have

110:57makes it so that doctors can live with this situation

111:01believing that it's optimal when it's a wreck.

111:04Yeah.

111:06Let me ask you the big, so as a physician,

111:10so everything you've seen, we've talked about 80%

111:13of the impact on health is lifestyle.

111:18How do we live longer?

111:20What advice would you give to general people?

111:22What space of ideas result in living longer

111:29and higher quality lives?

111:30Right, this is a very simple question to answer.

111:34Exercise for at least a half hour

111:37at least five times a week.

111:41Number one.

111:42Number two, don't smoke.

111:45Number three, maintain a reasonably healthy body weight.

111:49Some people argue that being lower than a BMI of 25

111:53is healthy.

111:54I think that may be true,

111:56but I think getting above 30 is unhealthy

112:00and that ought to be.

112:01Now that's largely impacted by socioeconomic status

112:07and we don't wanna blame the victims here.

112:09So we gotta understand that when we talk about

112:12all of these things, not cigarettes,

112:14but exercise and a good diet

112:18and maintaining a healthy body weight,

112:23we have to include in doing those things

112:27the impediments to people of lower socioeconomic status

§12Transcript · 1:52:32–2:02:21

112:32being able to make those changes.

112:34We've got to understand that personal responsibility

112:38accounts for some of this,

112:39but also social circumstances accounts for some of it.

112:44And back to your fish bowl analogy,

112:47if you're swimming in a fish bowl,

112:50if you live in a fish tank

112:51that's not being properly maintained,

112:53the approach wouldn't be to treat individual sick fish,

112:58it would be to fix your fish tank

113:01to get the bacteria out of it

113:03and whatever bad stuff is in there

113:05and make your fish tank healthier.

113:08Well, we invest far less than the other wealthy countries do.

113:12We're flipped, we have the mirror image

113:15in the spending on social determinants of health

113:19and medical determinants of health.

113:20We have exactly the wrong order.

113:23And not only does that choke off

113:25social determinants of health, which are very important,

113:28but actually just the ratio,

113:30even if you were spending,

113:32if we raise the social spending

113:35and raise our medical spending in proportion,

113:38it's the ratio of social spending to medical spending

113:41that's the problem.

113:42So, and why do we do that?

113:44Well, the answer is perfectly obvious

113:46that the way to transfer money

113:48from working Americans to investors

113:51is through the biomedical model,

113:54not through the social health model.

113:57And that's the problem for,

113:59and I'd like to discuss this

114:02because the market isn't gonna get us

114:06to a reasonable allocation.

114:08All the other wealthy countries

114:09that are so much healthier than we are

114:11and spending so much less than we are

114:14have some form of government intervention

114:17in the quality of the health data that's available,

114:20in the budgeting of health and social factors.

114:25And we don't, we're kind of the Wild West

114:28and we let the market determine those allocations.

114:31And it's an awful failure.

114:34It's a horrendous failure.

114:36So one argument against government,

114:39or sorry, an alternative to the government intervention

114:44is the market can work better

114:48if the citizenry has better information.

114:51So one argument is that

114:53communicators like podcasts and so on,

114:58but other channels of communication

115:01will be the way to fight big pharma.

115:03Your book is the way to,

115:05by providing information.

115:07The alternative to the government intervention

115:10on every aspect of this,

115:11including communication with the doctors

115:13is to provide them other information

115:15and not allow the market to provide that information

115:18by basically making it exciting

115:22to buy books, to make better and better communicators

115:27on Twitter, through books, through op eds,

115:30through podcasts, through so on.

115:32So basically, cause there's a lot of incentive

115:35to communicate against the messages of big pharma.

115:40There's incentive because people want to understand

115:43what's good for their lives

115:44and they're willing to listen to charismatic people

115:46that are able to clearly explain what is good for them.

115:50And they do, and more than 80% of people

115:54think that drugs cost too much

115:55and the drug industry is too interested in profits.

116:00But they still get influenced.

116:02They can't, you can't get the vote through Congress.

116:05You know, Democrats and Republicans alike

116:08are taking money from Congress

116:10and somehow it just doesn't work out

116:13that these even small changes.

116:17I mean, the pared down part of Medicare,

116:21the plan for increasing Medicare negotiation drug costs

116:27in Build Back Better,

116:29it's literally gonna reduce the number of new drugs

116:32that are beneficial, uniquely beneficial

116:37by about one new drug or two new drugs over 30 years.

116:42It will have virtually an indecipherable impact.

116:48And yet pharma is talking about the impact on innovation.

116:53And if you vote for this,

116:55if you let your Congressman vote for this,

116:58you're gonna severely slow down drug innovation

117:04and that's gonna affect the quality of your life.

117:07Let me ask you about over medication

117:17that we've been talking about from different angles.

117:19But one difficult question for me,

117:22I'll just, I'll pick one of the difficult topics,

117:25depression.

117:26So depression is a serious, painful condition

117:31that leads to a lot of people suffering in the world.

117:37And yet it is likely they were over prescribing

117:40antidepressants.

117:42So as a doctor, as a patient, as a healthcare system,

117:47as a society, what do we do with that fact

117:50that people suffer?

117:53There's a lot of people suffering from depression

117:57and there's also people suffering

117:59from over prescribing of antidepressants.

118:01Right.

118:02So a paper in the New England Journal by Eric Turner

118:06showed that the data,

118:09if you put all the data together from antidepressants,

118:12you find out that antidepressants are not effective

118:17for people who are depressed

118:19but don't have a major depression.

118:22Major depression is a serious problem.

118:25People can't function normally.

118:27They have a hard time getting out,

118:31performing their normal social roles.

118:35But what's happened is that the publicity,

118:39I mean, Prozac Nation was a good example

118:43of making the argument that why should people

118:45settle for normal happiness

118:47when they can have better than normal happiness?

118:49And if you're not having normal happiness,

118:52you should take a drug.

118:53Well, that concept that serotonin metabolism

119:00is the root cause of depression

119:03is really a destructive one.

119:05We have drugs that change serotonin metabolism

119:08but we don't know if that's why antidepressants

119:12work on major depression.

119:14And they certainly don't work on everybody

119:16with major depression.

119:16I forget what the number needed a treat is.

119:18I think it's around four,

119:20one out of four people have significant improvement.

119:23But the people without major depression don't get better.

119:28And the vast majority of these drugs

119:30are used for people without major depression.

119:33So what's happened is that the feelings

119:37of life satisfaction of happiness and not sadness

119:42have been medicalized.

119:43The normal range of feelings have been medicalized.

119:47And that's not to say that they shouldn't be attended to.

119:51But the evidence shows that attending to them

119:54by giving somebody a medicine doesn't help

119:57except that they feel like somebody cares about them

119:59and believes that they're suffering.

120:01But there are problems in living

120:04that give rise to much of this symptomatology

120:07of less than major depression.

120:10And let's call it what it is

120:12and figure out a way to help people

120:14in visual therapy, group therapy.

120:17Maybe lifestyle modification would work.

120:19We gotta try that.

120:21But let's call it what it is instead of saying,

120:24oh, you're in this vast basket of people who are depressed

120:29so we'll give you an antidepressant

120:31even though the evidence shows

120:33that people who are suffering from your level of depression

120:36don't get better.

120:38And that's a consequence of not focusing

120:42on preventative medicine, the lifestyle changes,

120:46all that kind of stuff.

120:47Well, yes, but it's really a consequence

120:49of the drug companies creating the impression

120:53that if you're sad, take a pill.

120:56If you're nonmajor depression,

121:01how do you overcome depression?

121:03Well, you have to talk about what the problem is.

121:06So talk therapy, lifestyle changes.

121:09Well, no, I'm not jumping to that.

121:12I'm saying that you ought to,

121:15A, the way you feel must be respected.

121:19Yeah, acknowledge that you're suffering.

121:21Acknowledge that you're suffering

121:22and deal with healthcare providers

121:24who acknowledge that you're suffering.

121:27So let's take that first step.

121:30And then. Big first step also.

121:32Big first step, yeah.

121:33Family docs are pretty good at that.

121:36That's kind of the arena

121:38that caused me to go into family medicine.

121:41The subjective experience of the patient.

121:44Okay, so you're a person

121:46who is not getting the enjoyment out of their life

121:49that they feel they ought to be getting.

121:52Now let's figure out why

121:54and whether that means some time with a social worker,

121:57some time with a psychiatrist,

121:59some time with a psychiatric nurse.

122:02I'm not sure how you'd best do that

122:04most effectively and efficiently,

122:05but that's what you need to do.

122:07And it may be that there's a marital problem

122:11and there's something going on

122:13and one of the spouses can't find satisfaction

122:18in the life they have to live within their relationship.

§13Transcript · 2:02:21–2:13:06

122:21Maybe there's a past history of trauma or abuse

122:24that somebody is projecting onto their current situation.

122:28Maybe there's socioeconomic circumstances

122:31where they can't find a job

122:33that gives them self respect and enough money to live.

122:36All, you know, an infinite range of things.

122:39But let's figure out, make a diagnosis first.

122:42The diagnosis isn't that the person feels sadder

122:45than they feel, than they want to feel.

122:48The diagnosis is why does the person feel sadder

122:51than they want to feel?

122:54You mentioned this is what made you want

122:56to get into family medicine.

123:00As a doctor, what do you think about the saying,

123:03save one life, save the world?

123:05This was always moving to me about doctors

123:13because you have like this human in front of you

123:17and your time is worth money.

123:22Your, what you prescribe and your efforts

123:26after the visit are worth money.

123:28And it seems like the task of the doctor

123:31is to not think about any of that.

123:34Or not the task, but it seems like a great doctor,

123:42despite all that, just forgets it all

123:45and just cares about the one human.

123:47And somehow that feels like the love and effort

123:51you put into helping one person

123:53is the thing that will save the world.

123:55It's not like some economic argument

123:58or some political argument or financial argument.

124:03It's a very human drive that ultimately

124:09is behind all of this that will do good for the world.

124:13Yes, I think that's true.

124:15And at the same time, I think it's equally true

124:19that all physicians need to have a sense of responsibility

124:23about how the common resources are allocated

124:28to serve the whole population's interest best.

124:34That's a tension that you have as a physician.

124:36Let's take the extreme example.

124:38Let's say you had a patient in front of you

124:41who if you gave one $10 billion pill to,

124:46you would save their life.

124:49I would just be tortured by that as a physician

124:52because I know that $10 billion spent properly

124:56in an epidemiologically guided way

125:00is gonna save a whole lot more lives than one life.

125:03So it's also your responsibility as a physician

125:06to walk away from that patient.

125:08I wouldn't say that.

125:10I think it's your responsibility

125:12to be tortured by it.

125:14That's exactly right.

125:17The human condition.

125:21That's a tough job, but yeah, yeah.

125:24To maintain your humanity through it all.

125:27Yeah, but you've been asking at different points

125:30in this conversation, why are doctors so complacent

125:35about the tremendous amount of money we're spending?

125:38Why do they accept knowledge from different sources

125:41that may not pan out when they really know the truth?

125:45And the answer is that they're trying to do their best

125:48for their patients.

125:49And there's this, it's the same kind of torture

125:56to figure out what the hell is going on with the data.

126:00And that's a sort of future project.

126:03And maybe people will read my book

126:06and maybe they'll get a little more excited about it,

126:08become more legitimate in practice.

126:10I would feel like my life was worthwhile if that happened.

126:13But at the same time, they've got to do something

126:17with the patient in front of them.

126:18They've got to make a decision.

126:21And they probably, there are not many weirdos like me

126:24who invest their life in figuring out

126:27what's behind the data.

126:28They're trying to get through the day

126:29and do the right thing for their patient.

126:31So they're tortured by that decision too.

126:34And so if you're not careful,

126:38big pharma can manipulate that drive

126:43to try to help the patient,

126:44that humanity of dealing with the uncertainty of it all.

126:49Like what is the best thing to do?

126:51Big pharma can step in and use money

126:53to manipulate that humanity.

126:55Yeah, I would state it quite differently.

126:57It's sort of an opt out rather than an opt in.

127:00Big pharma will do that.

127:02And you need to opt out of it.

127:07What advice would you give to a young person today

127:11in high school or college

127:13stepping into this complicated world

127:17full of advertisements, of big powerful institutions,

127:22of big rich companies,

127:24how to have a positive impact in the world,

127:27how to live a life they can be proud of?

127:30I would say should that person

127:34who has only good motives go into medicine.

127:38They have an inclination to go into medicine

127:39and they've asked me what I think about that

127:42given what I know about the undermining

127:45of American healthcare at this point.

127:47And my answer is if you've got the calling,

127:50you should do it.

127:52You should do it because nobody's gonna do it

127:54better than you.

127:56And if you don't have the calling

127:58and you're in it for the money,

128:01you're not gonna be proud of yourself.

128:03How do you prevent yourself from doing,

128:07from letting the system change you over years and years,

128:12like letting the game of pharmaceutical influence affect you?

128:20It's a very hard question

128:22because the sociologic norms are to be affected

128:28and to trust the sources of information

128:32that are largely controlled by the drug industry.

128:36And that's why I wrote Sickening,

128:38is to try and help those people in the medical profession

128:46to understand that what's going on right now looks normal

128:50but it's not.

128:52The health of Americans is going downhill.

128:55Our society's getting ruined by the money

128:57that's getting pulled out of other socially beneficial uses

129:02to pay for health care that is not helping us.

129:08So fundamentally, the thing that is normal,

129:12now question the normal, don't.

129:17If you conform, conform hesitantly.

129:21Well, you have to conform.

129:23You can't become a doctor without conforming.

129:26I just made it through.

129:30But there aren't many and it's hard work.

129:35But you have to conform.

129:38And even with my colleagues in my own practice,

129:40I couldn't convince them that some of the beliefs they had

129:44about how best to practice weren't accurate.

129:47There's one scene, a younger physician

129:51had prescribed hormone replacement therapy.

129:53This is back in 2000, 2001.

129:56Had prescribed hormone replacement therapy for one of my patients

130:00who happened to be a really good personal friend.

130:03And I saw that patient covering for my colleague at one point

130:08and I saw that her hormone replacement therapy had been renewed.

130:13And I said, are you having hot flashes or any problem?

130:15No, no, no, no.

130:16But Dr. So and So said it's better for my health.

130:21And I said, no, it's not.

130:23The research is showing that it's not, it's harmful for your health

130:26and I think you should stop it.

130:27So my colleague approached me when she saw the chart and said,

130:32wait a minute, that's my patient.

130:34Maybe your friend, but it's my patient.

130:37And I went to a conference from my alma mater, medical school,

130:43and they said that healthy people should be given hormone replacement.

130:47And I said, there's got to be a way to get rid of it.

130:51And I said, there's got to be drug companies involved in this.

130:55And she said, no, no, no, it was at my university.

130:57It was not a drug company thing.

130:59We didn't go to a Caribbean island.

131:02I said, do you have the syllabus?

131:03She said, yeah.

131:05And she went and got the syllabus and sure enough,

131:07it was sponsored by a drug company.

131:10They're everywhere.

131:11They're everywhere.

131:12And it's back to Kuhn that groups of experts

131:16share unspoken assumptions, and in order to be included

131:21in that group of experts, you have

131:23to share those unspoken assumptions.

131:25And what I'm hoping to do with my book, Sickening,

131:27and being here having this wonderful conversation with you

131:31is to create an alternative to this normal

131:36that people can pursue and practice better medicine

131:45and also prevent burnout.

131:47I mean, about half the doctors complain that they're burned

131:49out and they've had it.

131:51And I think that this is subjective.

131:54I don't have data on this.

131:55This is just my opinion.

131:57But I think that a lot of that burnout

131:59is so called moral injury from practicing in a way

132:04that the docs know isn't working.

132:08It's not actually providing an alternative to the normals,

132:12expanding the normals, shifting the normal,

132:13just like with Kuhn.

132:15You're basically looking to shift

132:19the way medicine is done to the original,

132:24to the intent that it represents the ideal of medicine,

132:29of health care.

132:30Yeah, in Kuhnian terms, to have a revolution.

132:33And that revolution would be to practice medicine

132:36in a way that will be epidemiologically most

132:40effective, not most profitable for the people

132:43who are providing you with what's called knowledge.

132:47You helped a lot of people, as a doctor, as an educator,

132:53live better lives, live longer.

132:56But you yourself are a mortal being.

132:59Do you think about your own mortality?

133:02Do you think about your death?

133:03Are you afraid of death?

133:06I'm not.

§14Transcript · 2:13:06–2:17:28

133:06I've faced it, been close.

133:12Yourself?

133:12Yeah, yeah.

133:14How do you think about it?

133:16What wisdom do you gain from having come close to death,

133:19the fact that the whole thing ends?

133:23It's liberating.

133:25It's very liberating.

133:26I'm serious.

133:27I was close, and not too long ago.

133:34And it was a sense of, this may be the way it ends.

133:41And I've done my best.

133:45It's not been perfect.

133:48And if it ends here, it ends here.

133:51The people around me are trying to do their best.

133:54And in fact, I got pulled out of it.

133:57But it didn't look like I was going to get pulled out of it.

134:01Are you ultimately grateful for the ride, even though it ends?

134:07Well, it's a little odd.

134:11I think so.

134:13If I know you can't take the ride if you know it's going to end well.

134:18It's not the real ride.

134:19It's just a ride.

134:22But having gone through the whole thing,

134:25I definitely freed me of a sense of anxiety about death.

134:31And it said to me, do your best every day,

134:35because it's going to end sometime.

134:38I apologize for the ridiculously big question.

134:40But what do you think is the meaning of life,

134:45of our human existence?

134:52I think it's to care about something and do your best with it.

134:56Whether it's being a doctor and trying

134:59to make sure that the greatest number of people

135:03get the best health care.

135:06Or it's a gardener who wants to have the most beautiful plants.

135:09Or it's a grandparent who wants to have a good relationship

135:12with their grandchildren.

135:13But whatever it is that gives you a sense of meaning,

135:19as long as it doesn't hurt other people,

135:21to really commit yourself to it.

135:24That commitment, being in that commitment for me

135:27is the meaning of life.

135:29Put your whole heart and soul into the thing.

135:34What is it, the Bukowski poem, go all the way.

135:38John, you're an incredible human being, incredible educator.

135:42Like I said, I recommend people listen to your lectures.

135:45It's so refreshing to see that clarity

135:47of thought and brilliance.

135:49And obviously, your criticism of Big Pharma

135:51or your illumination of the mechanisms of Big Pharma

135:56is really important at this time.

135:58So I really hope people read your book, Sickening,

136:02that's out today, or depending on when this comes out.

136:07Thank you so much for spending your extremely valuable time

136:11with me today.

136:12It was amazing.

136:13Well, Lex, I wanted back to you.

136:15Thanks for engaging in this conversation,

136:18for creating the space to have it,

136:21and creating a listenership that is

136:24interested in understanding serious ideas.

136:27And I really appreciate the conversation.

136:29And I should mention that offline,

136:30you told me you listened to the Gilbert Strang episode.

136:34So for anyone who don't know Gilbert Strang,

136:35another epic human being that you should check out.

136:39If you don't know anything about mathematics

136:41or linear algebra, go look him up.

136:43He's one of the great mathematics educators of all time.

136:46So of all the people you mentioned to me,

136:49I appreciate that you mentioned him,

136:50because he is a rockstar of mathematics.

136:54John, thank you so much for talking to us, it was awesome.

136:56Great, thank you.

136:57Thanks for listening to this conversation with John Abramson.

137:00To support this podcast,

137:02please check out our sponsors in the description.

137:04And now, let me leave you some words from Marcus Aurelius.

137:09"'Waste no time arguing about what a good man should be.

137:14Be one."

137:15Thank you for listening and hope to see you next time.

— A LITTLE MORE TO THINK ABOUT. —